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Tuberculosis (TB) presents a massive health care problem around the world and the rate of 
unfavourable outcomes after TB treatment remains unacceptably high.  The absence of a 
gold standard to determine when antibiotics have induced sterilising cure confounds the 
development of new approaches to treat pulmonary tuberculosis (PTB).   
Positron Emission Tomography/Computerised Tomography (PET/CT) is well established in 
the staging, treatment planning and response assessment of cancer.  In animal models, 18F-
FDG PET/CT has been used to accurately describe disease progression after infection and 
response to treatment in Pulmonary Tuberculosis (PTB) and human studies with small 
sample sizes have shown PET/CT to be promising in monitoring the effect of treatment using 
simple descriptive techniques. 
PET uptake intensity is influenced by numerous patient and equipment factors.  
Reproducible segmentation and quantification of lesions become particularly important in 
diseases with heterogenic morphology, vague lesion borders and multi-focal distribution 
throughout an organ or system, such as PTB. 
OBJECTIVE 
To discover if the functional and anatomical information gained by FDG PET/CT scans on 
patients with PTB before, during and after treatment can be applied to provide insight into 
the dynamics of Mycobacterium tuberculosis (MTB) versus host interaction, aid treatment 
response assessment and facilitate the discovery of biomarkers to monitor treatment 
response. 
METHODS 
We recruited 99 newly diagnosed adult, HIV-negative, PTB patients and performed PET/CT 
scans at diagnosis, month 1 and month 6 of treatment, as well as 1 year later.  We collected 
clinical specimens for microbiological testing and biomarker discovery.  Scans were 
evaluated qualitatively and we developed and implemented an automated technique to 
standardise uptake, segment lung lesions and quantify the scan information.  We compared 
the qualitative and quantitative data to clinical and microbiological outcomes. 
RESULTS 
We detected PET/CT imaging response patterns consistent with active disease plus the 
presence of MTB mRNA in sputum and bronchoalveolar lavage fluid in a substantial 
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proportion of PTB patients after standard treatment and one year later, including patients 
with a durable cure and others who later developed recurrent disease.  However, 
quantification of PET/CT parameters provided results that correlated very well with 
microbiological outcomes.  A large cavity volume was the best prognostic indicator of failure, 
while a suboptimal reduction in total glycolytic activity was the best prognostic indicator of 
recurrent disease.  Quantified results also showed promise to serve as reference in 
discovering novel biomarkers of treatment response. 
CONCLUSION 
The presence of MTB mRNA in the context of non-resolving and intensifying lesions on 
PET/CT might indicate ongoing transcription.  Thus, that even apparently curative PTB 
treatment may not eradicate all organisms in most patients, and points to an important 
complementary role for the immune response in maintaining a disease-free state.  The 
correlation of quantified scan characteristics with microbiological outcomes, provided insight 
into factors that influence successful treatment. The promising implementation of these 
parameters in biomarker discovery suggests that PET/CT might be a useful tool that leads to 
new, improved ways to monitor treatment response.   
  





Tuberkulose veroorsaak ‘n massiewe gesondheidsprobleem regoor die wêreld en die 
insidensie van slegte uitkomste na die afloop van behandeling is onaanvaarbaar hoog.  Die 
gebrek aan ‘n goue standaard om vas te stel of antibiotika steriliserende genesing bereik 
het, belemmer die ontwikkeling van nuwe metodes om tuberkulose te behandel. 
Positron Emmissie Topografie/Rekenaar Topografie (PET/RT) is ‘n gevestigde modaliteit in 
die diagnose, stadiëring en assesering van repons tot behandeling van kanker.  In diere 
studies is 18F-FDG-PET/RT reeds gebruik om die progressie ná infeksie en die reaksie tot 
behandeling van pulmonale tuberkulose (PTB) akkuraat aan te toon.  In voorlopige menslike 
studies het PET/RT ook belofte getoon in monitering van die effek van behandeling deur 
middel van eenvoudige beskrywende tegnieke.   
Die intensiteit van PET opname word beïnvloed deur verskeie eienskappe van die pasiënt 
en die toerusting.  Die konsekwente segmentasie en kwantifisering van letsels is van uiterste 
belang in siektes met heterogene morfologie, onduidelike grense en ‘n wye verspreiding 
deur ‘n orgaansisteem - soos in geval van PTB. 
Doelwitte 
Om te ontdek of die funksionele en anatomiese inligting wat verkry word deur PET/RT 
beeldings ondersoeke  op pasiënte voor, gedurende en na behandeling toegepas kan word 
om insig te gee in die dinamiese interaksies tussen Mycobacterium tuberculosis (MTB) en 
die gasheer. 
Metodes 
Ons het 99 nuut gediagnoseerde volwasse, HIV-negatiewe pasiënte met pulmonale TB 
gewerf en PET/CT skanderings uitgevoer by diagnose, asook maand 1 en maand 6 van 
behandeling; en 1 jaar na die afloop van behandeling.  Ons het kliniese monsters versamel 
vir mikrobiologiese toetse en biomerker ontdekking.  Ons het die beelde kwalitatief asseseer, 
asook ‘n ge-outomatiseerde metode om letsels te segmenteer en kwantifiseer ontwikkel en 
geïmplementeer. Die kwalitatiewe en kwantitatiewe uitslae is met kliniese en mikrobiologiese 
uitkomstes vergelyk. 
Resultate 
Ons het PET/RT respons patrone waargeneem wat inpas met aktiewe letsels, asook die 
teenwoordigheid van MTB mRNA in sputum en bronchoalveolêre spoeling vloeistof, in ‘n 
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substansiële getal pasiënte na standard TB behandeling en‘n jaar later - insluitende pasiënte 
wat genees is.  Die gekwantifiseerde resultate het wel baie goed met die mikrobiologiese 
uitkomstes gekorreleer.  ‘n Groot kaviteit volume was die beste prognostiese aanwyser van 
gefaalde behandeling en onvoldoende vermindering van die totale glikolitiese aktiwiteit was 
die beste aanwyser van herhalende PTB na behandeling.  Gekwantifiseerde resultate het 
ook belofte getoon as ‘n hulpmiddel in die ontdekking van nuwe biomerkers in perifere bloed 
van behandelings respons. 
Gevolgtrekking 
Die teenwoordigheid van MTB mRNA in die konteks van letsels wat nie opklaar nie en selfs 
intensifiseer op PET/RT, kan voortdurende transkripsie aandui.  Dit kan voorstel dat selfs 
ooglopend genesende PTB behandeling nie al die organismes in die gasheer eradikeer nie; 
en ‘n belangrike komplimentêre rol vir die van die immuunrespons om ‘n siekte-vrye 
toestand te handhaaf.  Die korrelasie van gekwanifiseerde beelding karakteristieke met 
mikrobiologiese uitkomstes en die belowende aanwending in biomerker ontdekking, stel voor 
dat dit tot potensiële hulp kan wees om behandelingsresponse beter te moniteer. 
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1. Introduction  
1.1 Context and overview of research project. 
I was given the opportunity to become part of the ‘Mycobacterium tuberculosis (MTB) 
biomarkers for diagnosis and cure’ project.  The project was a collaborative effort between 
the Stellenbosch University Immunology Research Group, the Tuberculosis Research 
Section of the National Institute of Allergy and Infectious Diseases, National Institutes of 
Health, the Catalysis Foundation for Health, the Center for Emerging Pathogens Rutgers-
New Jersey Medical School, the Center for Infectious Disease Research and the 
International Tuberculosis Research Center, Seoul, South Korea.  Funding was provided by 
the Catalysis Foundation for Health. 
The aim of the study was to recruit newly diagnosed patients with pulmonary tuberculosis in 
Cape Town and Seoul and observe them throughout treatment.  Serial collection of clinical 
data and established microbiological tests would be carried out.  18F-FDG PET/CT scans 
were to be performed at baseline and during treatment.  Since PET/CT scans have shown 
promise as a sensitive tool to monitor treatment response, the objective was to use the 
results in conjunction with the collected clinical and microbiological data to serve as a 
surrogate for MTB load.  In addition, to help identify patients who failed to reach sterilising 
cure, in spite of sputum culture negativity.  The combined surrogate would then be used to 
aid the discovery of novel biomarkers in collected body fluids: to correlate with MTB load, 
distinguish cure from unfavourable outcomes and shed light on underlying scientific 
mechanisms.  
We successfully completed recruitment and follow-up in Cape Town, however, due logistical 
problems, recruitment targets could not be met in Seoul. 
I came on board during the recruitment phase of the study. As a study clinician, I managed 
the nursing staff, supervised participant recruitment and assisted in procedures, like PET/CT 
scans and bronchoscopies.  I also reviewed test results from a clinical perspective and 
quickly got involved in scientific analysis.  The focus of my attention was drawn to the 
surprising PET/CT images:  the different lesion responses in the same pair of lungs and the 
persistence of lesions that appear active toward the end of treatment – even in cases that 
achieved clinical cure.  The nuclear physicians reporting the scans were baffled and 
research questions begged to be answered:  1) What are the implications of the 
inflammatory lesions at the end of treatment?  2)  Can specific scan characteristics be found 
that correspond to the clinical and microbiological information?  3)  Can these characteristics 
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be measured in a reproducible manner to serve as a reference for further biomarker 
discovery?   
To look for answers to the first question we applied for an amendment to the study protocol 
to perform bronchoscopies with alveolar lavage at the end of treatment and an additional 
PET/CT scan 1 year after the end of treatment on the subgroup of the participants that have 
not yet passed this time-point.  The bronchoalveolar lavage specimens were analysed for 
any evidence of persistent viable MTB, in spite of sputum culture negativity.  The additional 
scans were evaluated to observe the natural history of the persistent lesions seen at the end 
of treatment.  
I would like to provide an outline of this dissertation.   
The literature review, which follows this introduction, would firstly provide an overview of why 
it is important to find improved biomarkers.  It gives a summary of tuberculosis epidemiology 
and some detail about the rate of unsuccessful treatment and recurrence – emphasising the 
need for improved tuberculosis therapy.  I also discuss the shortfalls of tests that are 
currently used in programmatic healthcare and clinical trials to monitor the response to 
treatment, as well as the uncertainty that still exists when it comes to defining sterilising cure.  
The second section relates to PET/CT scans.  I first provide some background regarding the 
technology and most common applications.  Subsequently, I discuss very interesting results 
from PET/CT studies in animal TB models, as well as available literature on PET/CT scans 
in human patients with tuberculosis.  I discuss standard tools used to report PET/CT findings 
as reproducibly as possible, in addition to recently described techniques to segment lesions 
with limited user input, plus methods to normalise and quantify PET/CT scans. 
The last part of the introductory chapter 1 contains the research question and aims of the 
project. 
The second chapter contains the methods and procedures regarding the recruitment, follow-
up and medical management of participants, as well as research tests performed.  In this 
chapter, I describe how the scans were evaluated qualitatively and include a detailed 
description of how the operator independent technique to quantify scan images were 
developed and applied. 
The main results are separated into two chapters, each with a following chapter dedicated to 
a discussion of the respective results provided.  In chapter 3, I provide the participants’ 
demographical data and clinical outcomes, before documenting dynamic scan response 
patterns observed qualitatively and results of in depth microbiological sampling and testing 
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after standard treatment. The last section of chapter 3 is dedicated to extensive statistical 
testing exploring any meaningful or confounding associations between clinical profiles, 
microbiological test results and scan response patterns. Chapter 5 is dedicated to detailed 
results of the scan quantification by firstly discussing the performance of the user 
independent technique.  The subsequent section in the chapter explores the various 
quantified scan characteristics and how well different characteristics correlate (alone or in 
combinations) to clinical profiles and treatment outcomes at the different time-points.   
Chapter 7 is a relatively short chapter providing some preliminary results to serve as 
examples of how the quantified scan parameters are already being used as a reference for 
the discovery of novel biomarkers in peripheral blood. 
In chapter 8, I wrote a final wrap-up discussion and concluding remarks.   
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1.2 Literature review 
1.2.1 The challenge of tuberculosis 
TB incidence and treatment outcome 
Tuberculosis (TB), with an estimated 9,6 million new TB cases and 1,2 million TB related 
deaths in 2014 as well as increasing numbers of cases with drug-resistant strains, presents 
a massive health care problem around the world, particularly in low and middle-income 
countries like South Africa.1 
The current standard treatment period of 6 months for drug-sensitive TB was determined by 
acceptable rates of treatment failure and disease recurrence after discontinuation of 
chemotherapy.2  In literature, the reported rate of unfavourable outcomes varies 
considerably, however it is usually disconcerting.3  Unfavourable outcomes include failure to 
convert to sputum culture negative, treatment default and disease recurrence, which could 
be due to either endogenous relapse or exogenous reinfection.  Clinical trials utilise a strict 
inclusion and exclusion criteria, adherence counselling and monitoring.  In recently published 
multi-national trials failed treatment rates were relatively low and ranged from 1.3%–2.4%.  
Relapse rates within 12 – 24 months after successful standard treatment were somewhat 
higher at 2.6%,4 3%5 and 5%.6 Combined data from trials in Uganda, however found 
unsuccessful treatment outcomes (failure and default) in 8.5% of participants and a 
recurrence rate of 10%.7  Unsuccessful treatment reached 19% in a group of South-African 
miners and the relapse rate 9.7%8 
The outcome reported in programmatic conditions around the world, is considerably worse.  
According to the World Health Organisation’s (WHO) Global TB Report 2015,1 the global 
rate of unsuccessful treatment in HIV-negative patients with drug-sensitive (DS) TB is 12%. 
Of the 22 countries that carry 80% of the world's TB burden, 17 had unsuccessful treatment 
rates higher than 10%.  Five of these countries (including South Africa), as well as the 
greater African region, European region and the Region of Americas all report unsuccessful 
treatment rates greater than 20%. India, with the world’s largest absolute TB burden, and 
with low HIV co-infection rates (4%), reports unsuccessful treatment in 12 % of cases.  In 
addition, 18.5% of notified cases were recurrences.  Russia and Brazil, also listed as high 
burden countries, reported that respectively 36.1% and 16.1% of notified cases were 
recurrences. Although longitudinal data are not available in these reports, estimation based 
on other publications would suggest that more than half of the recurrent cases previously 
completed treatment within the previous 2 years.9–11 
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A recently published, population-based cohort study, conducted in Cape Town,9 
retrospectively followed up 2359 acid-fast bacilli (AFB) smear positive pulmonary 
tuberculosis (PTB) patients and found successful treatment in only 79.2%. Of the 1869 
patients (which included only 100 HIV co-infected cases) that successfully completed 
treatment, retreatment episodes were documented in 309 (16.5%), of which 286 were 
confirmed by AFB smear or culture.   Smear positive recurrence was detected in 203 cases, 
of which only 10 were HIV positive.  The median time to retreatment in these cases was 21 
months. The TB prevalence in Cape Town is sadly amongst the worst in the world,12 with the 
interesting note that the HIV co-infection rate is lower than in other high TB prevalence areas 
in South Africa.   
Thus, there exists discrepancy between trials and observational studies and national health 
programs, which may be due to the strict inclusion and exclusion criteria, as well as more 
active adherence counselling and monitoring. 
Clinical cure, sterilising cure and post-TB lung sequelae 
The absence of a fail-proof gold standard to determine when antibiotic treatment has 
induced sterilising cure in PTB confounds new approaches for measuring treatment 
response.  Although it has been suggested that in trials, follow-up after treatment could be 
shortened due the most frequent timing of relapse, the standard follow-up period for phase 3 
TB treatment trials is 18 – 24 months after treatment completion13.  This greatly contributes 
to the costly and time-consuming nature of trials testing new TB treatment approaches.   
The current treatment response measurement recommended by the WHO is still based on 
sputum AFB smear.14 AFB smear positivity is only 61% - 70% when compared to MTB 
culture at baseline.15 A meta-analysis, found smear positivity at month 2 and month 5 a poor 
predictor of outcome.16  The pooled sensitivity for a positive month 2 smear to predict 
treatment failure was 57% and 24% to predict recurrence [positive predictive value (PPV) of 
9% and 10%] with a specificity of respectively 81% and 85% [negative predictive value 
(NPV) of 98% and 93%].  A positive month 2 sputum culture performed only slightly better, 
found to be 40% sensitive and 85% specific for relapse.  Month 2 culture conversion in liquid 
media has also been suggested as a surrogate marker for favourable response to treatment, 
but has not been proven to be accurate enough.13,17   
Shortening treatment is also a major aim of anti-tuberculosis drug development.18  Four 
trials4–6 introduced an experimental  4-month treatment arm, which yielded significantly 
increased relapse rates, even though sputum culture conversion rates were higher within the 
first 2 months of treatment.4–6,19,20 The first trial selected low-risk patients, based on a criteria 
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requiring absence of cavities on baseline chest x-ray and sputum culture conversion by 
month 2.19 The three other trials tested treatment regimens, respectively containing: 
Gatifloxacin,6 Rifapentine with Moxifloxacin,5 or Moxifloxacin4 to replace components of 
standard therapy.  These regimens appeared promising in pre-clinical studies to induce 
more rapid MTB killing and culture negativity.  The increased relapse rates, in spite of earlier 
culture negativity, strongly suggests that Mycobacterium tuberculosis (MTB) can persist in 
lung tissue for months to years after culture negativity has been achieved through antibiotics 
and the important role that MTB sub-populations (unculturable in sputum) plays in TB 
treatment relapse.  It also suggests a need for better understanding the scientific mechanism 
of a favourable clinical response to TB treatment.20 
In contrast to sputum culture conversion, lung lesions seen on chest X-ray (CXR) or 
computed tomography (CT) often persist long after the end of successful treatment.21,22 A 
retrospective Korean study analysed CT scans before and after PTB treatment in 66 patients 
and found a reduction in lesion size in 61 (92%) of the cohort.  Thirty-three patients (50%), 
however, still had at least one lesion with features consistent with active disease.  None of 
the patients relapsed in the 15 month follow-up period, thus no causal link between residual 
lesions and relapse was found.21  A chest x-ray severity grading score showed 80% 
reduction during standard TB treatment, but not complete resolution in most cases.22  The 
score did show promise as a clinical outcome predictor, but this could not be validated in a 
separate study.23   
Similar to residual lung lesions, persistent symptoms and signs after microbiologically 
confirmed cure are also common, due to post tuberculosis lung impairment.24–26  Lung 
impairment after TB disease could be due to a restrictive pattern (loss of forced vital 
capacity), an obstructive pattern (decreased forced expiratory volume), or a combination of 
both.  Lung impairment is present to varying degrees in most cases after the successful 
treatment of pulmonary tuberculosis.27–29  Both these patterns of functional impairment 
increase incrementally after repeated episodes of PTB.28 The Post tuberculosis pulmonary 
impairment contributes roughly 75% of TB-related disability burden.30   
Another tool used for TB diagnosis, the polymerase chain reaction-based, GeneXpert 
MTB/Rif assay (Xpert) remains positive after treatment in roughly 30% of clinically cured 
patients.31,32 This is believed to be due to the relative stability of MTB DNA in alive and dead 
cells. 
The persistence of lung lesions, clinical symptoms and MTB DNA after clinical cure, is in 
contrast to sputum culture negativity before sterilising cure.  This contributes to uncertainty 
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when defining sterilising cure and indicate a great need for improved methods to measure 
treatment response.  
The need for a protracted treatment duration with multiple anti-TB agents, can in part, be 
explained by the presence of sub-populations of slow-replicating MTB that are naturally 
tolerant to all TB drugs.33 Anti-tuberculosis therapy introduces a selection process, and 
surviving MTB are progressively slower to replicate and more tolerant to drugs.  Slow-
replicating MTB are also more difficult to grow in culture mediums, which can manifest as 
persistent, viable, non-culturable MTB. This has been demonstrated in mice after 14 weeks 
of isoniazid and pyrazinamide treatment when MTB mRNA transcripts (shown to be absent 
in dead bacteria in vitro) were detected in culture negative tissue from all mice necropsied at 
this time-point.  High-dose steroid-induced bacteriological relapse occurred in 21 of 23 mice 
that were followed up34.   The presence of mRNA could suggest transcriptionally active 
bacteria due to its very short half-life (on average 9.5 minutes for MTB in vitro), although 
stabilisation of transcripts occurs when exposing the intact MTB to stresses (cold shock and 
hypoxia) and therefore the in vivo half-life is not known.35   
The retention of low-abundance mRNA and a relative increase of non-coding RNA  in 
dormant MTB have been shown during in vitro persistence induced by potassium depletion 
and Rifampicin exposure and might play a role in early reactiviation.36 Persistent bacteria 
have, to date, not been observed in humans as they have been in mice and in vitro culture. 
Slow replicating, resilient MTB are also selected by stress induced by the immune response.  
It has been shown that the MTB cultured from sputum, mostly originate from the wall surface 
of cavities that communicate with the airways.  On histology, this area harbours the most 
abundant bacterial load, as well as the most actively replicating populations of bacteria.  
Other lesion types harbour much lower numbers of bacteria and those that are present in 
these lesions, have shown an altered metabolic state which make them more resistant to 
growth in culture.37  These bacteria may play an important role in endogenous relapse. 
Several different MTB virulence factors have been identified.38  They include: 1) promotors of 
growth and metabolism, such as enzymes of lipid pathways, cell wall mediators, regulatory 
systems.  2) factors that protect against the stressors of host defence, such as nitrosative 
and oxidative stress, phagosome inhibition and latency.  3) specific virulence compounds, 
like proteases, secretion systems and sigma factors. These factors varies between strains 
and between different phenotypes, contributing to different manifestations of TB pathology 
and levels of drug tolerance.39  The Beijing strain is described as an especially virulent 
strain, It predominates geographical areas (including the Western Cape) and has been 
associated with outbreaks world-wide.40 MTB virulence factors also play a role in treatment 
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response and the Beijing strain has been linked to a higher risk of persistent culture positivity 
after treatment (failure).41,42   
In addition to bacterial factors, multiple patient related factors influence severity of TB 
disease and treatment response.  Poor adherence, cavitatory or extensive lung lesions and 
impaired immunity (e.g. HIV and diabetes) are all associated with a higher incidence of 
treatment failure and relapse.  7,8,17,43   
An adequate response to treatment, firstly require adherence.43  Apart from adherence, 
multiple factors could lead to substandard drug absorption, which are also independently 
associated with an unfavourable outcome.44,45  In an animal model46 and a study on (human) 
spinal TB,47 drug concentrations were shown to vary widely, influenced by the type of lesion 
and the individual drug.   
Conditions leading to impaired immunity, such as HIV and diabetes, are also independent 
risk factors for disseminated disease and an unfavourable treatment outcome – in spite of a 
tendency to be associated with less cavitation and a higher incidence of sputum culture 
negative TB.8,9,17,43  This further highlights the pitfalls of using sputum culture as a measure 
of treatment response and suggests an important complimentary role of the immune system 
in a successful response to treatment.  
1.2.2 18F-Fluorodeoxyglucose positron emission tomography and computed 
tomography (PET/CT) 
Background 
Positron Emission Tomography/Computerised Tomography (PET/CT) is well established in 
the staging, treatment planning and response assessment of cancer and various 
inflammatory and infectious diseases.48,49  18F-fluorodeoxyglucose (FDG) is the most 
commonly used PET tracer.  It reflects glucose metabolism and shows increased uptake in 
areas of inflammation.  PET scanners measure the radiopharmaceutical concentration in 
tissue (kBq/ml).50–52   
Uptake intensity in tissue is variable and influenced by numerous patient and equipment 
factors, which is why the lesion- to- background ratio is often a more robust measure.53 
Several semi-quantitative measurements of intensity have been developed, of which, 
Standardised Uptake Value (SUV), is most commonly used and compensates for variation in 
body size, injected activity and decay.  It uses the formula:   





𝐼𝑛𝑗𝑒𝑐𝑡𝑒𝑑 𝑑𝑜𝑠𝑒 (𝑀𝐵𝑞) .  𝑝𝑎𝑡𝑖𝑒𝑛𝑡′𝑠 𝑤𝑒𝑖𝑔ℎ𝑡 (𝑘𝑔)
   




Segmentation of the Metabolic Tumour Volume (MTV), i.e. the anatomical volume of the 
FDG-avid lesion, is essential for the generation of more comprehensive parameters.  The 
simplest method to quantify a lesion uses the most intense voxel in the lesion (SUVmax).  
This, however, is prone to variability and disregards information from the remainder of the 
lesion.  The MTV allows the mean (SUVmean) to be calculated. Total Glycolytic Activity (TGA) 
is the product of the mean intensity (SUVmean) and the volume of an area of interest. 50,51,54–56 
SUV, however, are also influenced by most of the same factors influencing uptake intensity, 
such as body composition, with an overestimation of intensity occurring in obese 
patients.53,57  Using the body surface area or the lean body mass to calculate the SUV have 
been proposed to compensate for this.  A high blood glucose concentration reduce FDG 
uptake in tissue and needs to be well controlled prior to FDG administration.  Time between 
administration and image acquisition should also be optimised and standardised to improve 
consistency in results.  The body’s surface and other anatomical structures cause scatter 
and attenuation of the radio-signal derived from FDG.  This is usually partially corrected by 
computer algorithms using anatomical data from the CT scan during reconstruction of the 
images.58  Many different algorithms are used for attenuation correction and reconstruction 
of the PET images, adding to inter-scanner variability. 
Animal PET/CT studies 
In mouse, rabbit and primate models, FDG PET/CT has been used to accurately display the 
progression of disease after exposure to Mycobacterium tuberculosis (MTB) and the 
response to treatment.59–62   
Via et al. (2012) provided a detailed documentation of the dynamics of lung lesions on PET-
CT in rabbits after infection with MTB and also after treatment initiation.61  After infection with 
MTB by aerosol, serial PET/CT’s were performed and animals necropsied at various time-
points.  In tissue, the CFU (colony forming units) count raised within the first 2 weeks, while 
granulomatous lesions became apparent on histology by 4–5 weeks.  The bacterial load also 
peaked at this stage.  After that time-point, the CFU count dropped somewhat and stabilised, 
as the animals entered the chronic phase of infection.  On PET/CT, a mild, homogenous 
increase in background lung uptake was noticed and FDG-avid lung nodules were seen from 
week 4.  After week 4, the progression of individual lesions were found to be markedly 
different.  Some continued to get bigger, others formed cavities and some resolved.  If a 
lesion was in the process of resolving, the individual lesions showed decreasing PET 
intensity, followed by a reduction in density on CT before ultimate volume reduction.  After 
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the increase in FDG-avidity and CT density of lesions during the acute phase, the chronic 
phase of infection coincided with a stabilisation of the SUVmax.  The maximum CT density in 
the lung and the percentage of lung volume affected also stabilised, but dynamic changes 
were still found in individual lesions.   
On rifampicin or isoniazid treatment, a significant and progressive reduction in lesions’ FDG-
avidity was seen from week 1, with a sharp decrease towards week 4 and some stabilisation 
toward week 8.  This was closely followed by a reduction in CT density and ultimate volume 
loss.  In untreated rabbits there were a trend for some correlation between FDG-avidity in 
lesions and bacterial numbers, while a significant correlation was found between FDG-
avidity (measured in SUVmax) and both pathology and bacterial numbers.   
Similar responses were shown in MTB infected cynomolgus macaques in collective works by 
Lin, Coleman, Flynn at al.59,62–64  Additionally, this also provided a model of latency64:  some 
animals progressed to active disease, while others managed to suppress the initial infection 
and maintain latency.  The course of latent disease was characterised by some FDG-avid 
granulomas (visualised as small nodules on scan) and increased lymph node intensity within 
3 weeks of infection. The nodes and the granulomas in latent disease typically did not 
progress and resolved over time.  Progress to active disease was characterised by 
comparatively more nodules at week 3, which showed a rapid increase in number, size and 
uptake intensity over the course of the following 4 to 5 weeks.  At that stage, the lymph node 
intensity in this group also tended to be higher.  The course of individual lesions varied in 
terms of size and SUV intensity within the same host, while the central tendency of lesion 
size, SUV intensity and numbers within a host was associated with outcome.  This report 
also noted the ‘percolator’ phenomenon in one primate, referring to a state between latency 
and active disease, characterised by steady state of individual lesion changes, without 
progress to overt deterioration in clinical state of the host.  Macaques showed a similar 
response to anti-TB treatment compared to rabbits.59  In untreated subjects, the SUV 
intensity of lesions weakly correlated to the M. tuberculosis CFU count, while a good 
correlation with size and MTB load were found.62  On treatment, the reduction in SUV 
showed a negative correlation with the activity of the chemotherapy used and also correlated 
with the CFU counts.59  On mono-therapy, there were individual lesions that increased in 
size and SUV and residual activity in apparently sterilised lesions were also noted in some 
cases.59 
There are also some other notable animal models found in literature.  A difference in the 
disease progression and complications were noticed on scans of Marmosets infected with 
MTB strains with different virulence factors.65 In a mouse model, PET/CT was also able to 
detect the development of relapse before microbiological evidence.66   
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Human PET/CT studies 
There are relatively few reports available in literature regarding the potential use of PET/CT 
scans in tuberculosis.   
 PET/CT has been used to determine the risk of malignancy in solitary pulmonary nodules.  
The use of PET/CT has reduced the number of unnecessary thoracotomies.67  PET/CT is 
also used to evaluate mediastinal lymph nodes in staging non-small-cell lung cancer, to 
provide a prognosis and guide treatment.68  In both indications, however, the accuracy 
decreased in TB endemic areas, due to the overlap between the range of lesion PET 
intensities associated with malignancies and TB, thus introducing the need for adjusted 
diagnostic thresholds and reducing the benefit of PET/CT.67–69Human studies with small 
sample sizes have shown promise in using PET/CT as a tool to monitor TB treatment 
response.  A prospective study found decreased uptake intensity after 1 month treatment of 
pulmonary (n=10) and extra-pulmonary (n=10) TB.70 The authors reported a 31% median 
decline in the SUVmax of each individual’s most intense lesion (range 2%—84%).   
Due to the invasive procedures required in getting a tissue specimen for culture and the 
longer treatment duration required (12—18 months), spinal tuberculosis has sparked an 
interest in the possible use of PET to monitor treatment response.  A small prospective study  
showed a steady decline in lesion uptake intensity (measured in SUVmax) after 6, 12 and 18 
months of treatment for spinal TB (n=18).71 The mean improvement in the first 6 months 
were 57% and at month 18, the SUVmax ranged between 1.1 and 2.4.  A Japanese study 
reported the PET/CT findings of patients with MTB and Mycobacterium Avium Complex 
disease over the course of treatment.  Scan findings and responses in the two groups were 
very similar.  Treatment duration for the MTB group were 12 months and in the eight MTB 
patients that a had follow up scan after the end of treatment, no lesions with significantly 
increased uptake were found.72  A European study on 35 patients with pulmonary or extra-
pulmonary TB reported persistent PET/CT lesions in 15 and progressive lesions in four 
patients after a mean treatment duration of 16.1 months.73  In patients with TB and HIV co-
infection PET/CT has shown promise to predict treatment response based on the amount of 
lymph-node bastions involved at baseline.74 
In a trial, linezolid was added to the therapy of patients with extensively drug-resistant (XDR) 
PTB and PET/CT scans were performed at baseline, month 6 and either month 1 (n=4), 2 
(n=4) or 3 (n=5).  Whole lung analysis with fixed threshold were performed on the scans and 
showed a decrease in total glycolytic activity (TGA) and Gross Tumour Volume (GTV) over 
the treatment period, when compared to patients not receiving the additional chemotherapy.  
The most marked improvement was noted within the first month.60   
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Another trial tracked the quantified changes from baseline on PET/CT after 2months and CT 
after 6 months of treatment in 28 patients with multi-drug resistant (MDR) TB.75  The 
investigators made use of whole lung quantification of PET, using fixed thresholds; and 
reader scores to describe the CT.  Quantified measures of PET images showed less inter-
reader variability than CT reader scores. The reduction in total glycolytic activity over 2 
months accurately predicted outcome, while CT volume changes at month 6 were also 
predictive.  This study also throuroughly documented the density ranges associated with 
different lesion morphology on CT.  Nodules and tree-in-bud lesions were usually between -
500 and -200 Hounsfield Units (HU). Bronchial thickening was from -300 to 100 HU and 
more established lesions, such as consolidation; cavity walls, fibrosis and collapse usually 
showed densities between -100 and 100 HU.   
PET/CT lesion segmentation 
During segmentation, the borders of the metabolic tumour volume can be delineated visually 
or using various semi-automated techniques including thresholding or gradient-based 
boundary techniques.  However no single technique proven optimal for all applications.53  
Lesion delineation in most cases is still performed manually, based on visual interpretation of 
PET or CT images.  This is prone to inter- and intra-operator variation, especially for PET, 
due to the difficulty of delineating anatomical boundaries using functional information, in 
addition to low resolution and inherent noise.55–57,76–80  
Multiple methods are used and proposed to decrease variation in lesion segmentation.  
These include using reference values to normalise the lesion to background uptake intensity 
by comparison to liver or mediastinal blood pool uptake.81–83  A five-point grading system, 
referred to as the Deauville score, is commonly used as a standard aid in describing lesion 
intensity in clinical reporting and density:  1) No uptake above background.  2) Lesion 
intensity equal or less than the mediastinal blood pool.  2)  More uptake than the 
mediastinum, but equal or less than the liver.  Uptake moderately increased compared to the 
liver.  5)  Uptake markedly increased compared to the liver at any site. 
Reproducible segmentation and quantification become particularly important in diseases with 
heterogenic morphology, vague borders and multi-focal distribution throughout an organ or 
system, such as TB or Sarcoidosis.60,75  This is especially important when accurate tracking 
of changes over time is required.  To account for the spatially complex lesions associated 
with pulmonary tuberculosis, computer aided segmentation, based on affinity propagation, 
has shown high accuracy and increased efficiency when tested in PET images of TB 
infected rabbits.84  
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Evaluating the accuracy of lesion segmentation techniques can also prove to be challenging.  
A ground truth (objective gold standard segmentation), to measure the segmented volume 
against must be established.  The gold standard is histology – although it can be difficult to 
compare the size of a tissue sample after surgical removal to a scan before removal.  In the 
absence of histology, the technique could be measured by testing it on a phantom scan, but 
this could not always be compared to real-life physiology.  Another option is creating a 
surrogate ground truth, by getting one or more experts to delineate the boundaries of the 
lesion.  If more than one expert is employed, the different segmentations is statistically 
combined.   
The most commonly used segmentation technique relies on thresholding.53  Fixed 
thresholding delineates the voxels above an assigned intensity value.  Adaptive thresholding 
uses an assigned scan specific background reference and one of various analytical 
expressions to determine the edges of the segment.  Region-based segmentation usually 
requires the user to define a point in the lesion and the technique delineates the boundaries 
according to the gradient.  More complex computer learning-based methods are also used.  
The ‘fuzzy-locally-adaptive Bayesian’ method has shown to be robust and reproducible.  
This uses the spatial relationship of the ‘fuzzy’ (difficult to classify) areas to the lesion or 
background segments to choose to which class it belongs.  However, it has also show 
variable accuracy in heterogenic lesions.85  
A phantom study compared 6 different proposed auto-segmentation methods and found 
adaptive thresholding techniques using a reference normal background volume of interest 
(VOI) in the formulas to improve accuracy.80  
Some work has also concentrated on the quantification of CT.  CT images, acquired with 
PET provide anatomical information.  CT scanners measure the radio-opacity, or density of 
anatomical structures and lesions in Hounsfield Units (HU).  It is not a functional scan and is 
less prone to variability.  Joint-segmentation, which implies using information from both 
modalities, of fused PET and CT images have shown improved robustness.86  Only a few 
studies have evaluated densometric quanitification of CT scans in diffuse lung disease. 87–90  
It appeared to be reproducible and correlate well with other disease markers.  It was used to 
successfully track changes over time in patients with idiopathic pulmonary fibrosis.88  In 
interstitial lung disease, quantitated CT indexes correlated well  with lung function tests.90  
  
Stellenbosch University  https://scholar.sun.ac.za
14 
 
1.3 Research Justification 
1.3.1 Research question 
Can the functional and anatomical information gained by 18F-FDG PET/CT scans on 
patients with PTB before, during and after treatment be applied to provide insight into the 
dynamics of MTB versus host interaction, aid clinical treatment response monitoring and 
facilitate the discovery of biomarkers to monitor treatment response? 
1.3.2 Study objectives 
 Recruitment and follow of patients newly diagnosed with sputum positive pulmonary 
tuberculosis. 
 Perform 18F-FDG PET/CT scans at diagnosis, after 1 month and after 6 months of 
standard anti-tuberculosis treatment and collect clinical specimens for biomarker 
discovery. 
 Define clinical outcome categories based on established tests, namely Chest X-rays, 
sputum culture microbiology and symptom monitoring. 
 Qualitative description of the scans. 
 Development of technique to quantify scan information. 
 Use developed technique to quantify scans. 
 Comparison and correlation of qualitative and quantitative PET/CT data to defined 
clinical outcomes to identify positive and negative prognostic scan characteristics. 
 Comparison and correlation of biomarkers in clinical samples to most accurate 
PET/CT characteristics to aid discovery, understanding and ultimate implementation 
of these markers. 
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2. Methods and procedures 
2.1 Patient recruitment and follow-up 
Ethical approval was obtained for all study related activities from the Stellenbosch University 
Human Research Ethics Committee (registration number N10/01/013), as well as City Of 
Cape Town Health department and Tygerberg Hospital management.  In total, 131 HIV-
uninfected adults with newly diagnosed pulmonary tuberculosis (PTB), confirmed by sputum 
culture, were recruited after informed consent between April 2010 and April 2013 at Primary 
Healthcare Clinics (PHC’s) in Cape Town.  Of these patients, 32 were excluded for reasons 
including: missed scan visits due to technical reasons (7), patient decision (8), sputum 
culture negativity at diagnosis (8) and severe co-morbidity (3). We did not consider patients 
who received TB treatment within the previous 12 months. 
Sputum specimens for MGIT culture with speciation and additional clinical information were 
collected at Day 0, week 1, 4, 8, 12, and 24 (month 6) for all participants and an additional 
culture, collected at week 20 for the last 64 patients who completed the study.  Of the 99 
completing study time-points, 85 patients were also available for a formal follow-up study 
visit 1 year after the end of treatment, while the other cured patients were screened by 
telephonic interview and review of medical records and results.  The screen was repeated 
for all participants, 2 years after the end of treatment.  Patients' clinical outcomes were 
classified as cured if they proved and maintained sputum culture negativity by month 6 (M6), 
failed treatment if they’re M6 culture was still positive, un-evaluable if contamination caused 
uncertainty in outcome, and recurrent if they were restarted on TB treatment by healthcare 
providers in the 2 years after initial treatment completion.  Sputum and scans were obtained 
6 months after initiation of treatment, while BAL fluid was always collected after the end of 
treatment.  Bronchoscopies were performed on PTB patient who did not yet pass this time 
point by the time ethical approval was granted for this procedure.  Adequate volume BAL 
fluid for RNA extraction was obtained for 15 of these patients. 
Sixty-six community controls and 13 controls diagnosed with infective or inflammatory lung 
diseases other than PTB (other lung disease; OLD) were recruited from the same 
community.  Out of this group, 20 community and 5 OLD consecutively enrolled controls 
were included in sputum RNA analysis.  OLD controls included four cases of pneumonia and 
one asthma exacerbation case.  Active tuberculosis was excluded for all controls based on 
negative sputum culture and a chest X-ray not suggestive of PTB.  All controls were HIV-
negative and not on any systemic corticosteroid treatment.  Figure 1 shows a diagram of 
recruitment, follow-up and procedures. 





Figure 1:  Flow chart of study design. 
(a) In, South-Africa, 99 sputum culture positive Pulmonary Tuberculosis (PTB) patients underwent 
18F-FDG PET-CT scans at diagnosis (Dx), month 1 (M1) and month 6 (M6) of treatment.  Fifty 
patients also had PET-CT scans 1 year after the end of treatment (EOT + 1y).  QRT-PCR assays for 
MTB mRNA were performed on month 6 sputum from 75 patients and end of treatment 
bronchoalveolar lavage (BAL) samples of 15 patients.  (b) QRT-PCR assays were repeated on 
sputum from 20 community controls, and 5 controls with lung disease other than PTB; as well as BAL 
samples of 10 controls undergoing diagnostic bronchoscopies for suspected lung cancer.  (c) PET-CT 
scans were also performed on 14 sputum culture positive PTB patients from South Korea at Dx, M1 
and M6.  
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2.2 Treatment regimen 
All patients were subjected to directly observed treatment (DOT) at local healthcare clinics. 
Seventy-two patients received a standard treatment regimen, consisting of a two months 
intensive phase with daily fixed-dose combination tablets (HRZE) consisting of isoniazid 
(INH), rifampicin (RIF), ethambutol (EMB) and pyrazinamide (PZA) followed by a 4 month 
continuation phase of daily INH and RIF (currently the standard of care according to the 
WHO guidelines).14  Twenty-three patients received an extended regimen:  3 months 
initiation phase of HRZE, with additional streptomycin in the first month (19) or without (4), 
and a 5 months continuation phase.  In 22 patients, the indication for the extended regimen 
was previous episode(s) of PTB and for the remaining patient, delayed smear conversion.  
The local guidelines were amended during the study period to standard 6 months of HRZE 
treatment for all drug-susceptible cases, resulting in seven patients with previous episode(s) 
not receiving extended treatment. 
Two patients had INH mono-resistance and received 6 months of HRZE with added 
ofloxacin and 12 months of HRZE respectively.  Two patients with MDR received 
individualised regimens, containing kanamycin and terizidone among others.   
Clinical outcome after 6 months of treatment was classified according to time to maintained 
sputum culture negativity (TTN).  Patients were classified as: cured if they proved and 
maintained sputum culture negativity by M6; failed treatment if their M6 culture was still 
positive; un-evaluable if contamination caused uncertainty in outcome; and recurrent if they 
were restarted on TB treatment in the 2 years after initial treatment completion.  None of the 
un-evaluable group was diagnosed by healthcare providers with recurrent PTB before EOT 
+ 2y.  
2.3 Recruitment and follow-up, South-Korea 
All participants signed informed consent (Ethical approval from National Medical Centre 
Institutional Review board: IRB00008343).  19 culture positive PTB patients were recruited 
at diagnosis in Masan, South Korea.  Three patients were lost to follow-up and 2 decided to 
leave the study.  The 14 patients that completed Dx, M1 and M6 scans included 3 with MDR 
strains and 2 with Rifampicin mono-resistance.  Patients with DS-PTB were treated with 
standard HRZE for 6 months, Rifampicin resistant cases were treated for 12 months and 
MDR cases were treated for 18 months after culture conversion, on individualised regimens. 
Patients were followed up for 2 years after treatment. 
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2.4 18F-FDG PET/CT scanner protocol 
A one-week window was allowed for the Dx and M1 scans, while a 4-week window was 
allowed for M6 and EOT + 1y year scans.  Scans were performed at Panorama Mediclinic or 
Tygerberg Hospital, using a Siemens Biograph or Philips Gemini scanner respectively, both 
of which were equipped with a 16 slice CT scanner.  Patients fasted for at least 6 hours 
before FDG administration, while being encouraged to drink plenty of water.  According to 
body weight 185-259MBq of 18F -FDG was administered intravenously 60 min before scan. 
Scans at baseline were performed from the base of skull to the upper thigh and from the 
neck to the upper abdomen (whole lung) at M1, M6 and EOT + 1y.  PET images were 
reconstructed to 4x4x4 mm voxels using an iterative algorithm. The CT scan parameters 
were set at 120kV, 100mAs without dose modulation with 1.17x1.17 mm pixels and a 3 mm 
slice thickness. 
2.5 Qualitative analysis of PET/CT images 
CT and PET images were evaluated in collaboration and consensus with a radiologist, a 
nuclear physician and a pulmonologist.  Patient clinical outcomes were not known at the time 
of reading.  Lesion morphology was characterised and measured based on CT images.  PET 
uptake intensity of prominent lesions was measured using the mean and maximum 
standardised uptake value (SUV) and compared across time-points, using the uptake in the 
right lobe of the liver and the mediastinal aortic blood pool, as reference values to account 
for variability in background uptake.50,54–56,77–79,81 
The most intense lesion of each scan was ranked based on its mean standard uptake value 
(SUVmean).  The method was adapted from the Deauville grading system that used the 
mediastinal blood pool and liver as references.81–83 a) None: No increased uptake compared 
to surrounding lung tissue.  b) Minimal:  Uptake more intense than surrounding lung tissue, 
but less intense than mean (SUV) of 10 mm sphere in mediastinal blood pool.  c) Mild:  
Uptake more intense than mediastinal blood pool but less than 1 standard deviation (SD) 
below the mean SUV of a 30 mm sphere in right liver lobe.  d) Moderate:  Uptake similar to 
liver (between 1 SD below mean SUV and 2 SD above mean SUV).  e) High: Uptake more 
intense than 2 SD above mean liver SUV and less than double the mean liver SUV.  f)  Very 
high:  Intensity higher than double the mean liver SUV. 
Scans were then grouped into response patterns by comparing each M6 lesion to the 
corresponding M1 lesion to summarise the central trend of lesion progression: 1) Resolved, 
2) Improved and 3) Mixed.  Resolved response pattern refers to minimal or no increased 
FDG uptake compared to surrounding healthy tissue, regardless of structural abnormalities 
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on CT.  Improved scans had decreased intensity of all lesions compared to the baseline 
scan, but still one or more lesion(s) with increased uptake compared to surrounding lung 
tissue and reference structures.  Mixed responses showed at least one new FDG-avid lesion 
or at least one lesion with increased FDG uptake (intensified) compared to the baseline 
scan. 
2.6 Quantitative analysis of PET/CT images  
Pre-processing 
Images were exported from the PET/CT workstation in DICOM format and converted to 
ANALYZE format using MRIConvert.91 To ensure reproducibility and facilitate direct 
comparison, each patient’s baseline and follow-up scans were co-registered, using 
Statistical Parametric Mapping (SPM 8)92 with Matlab 2013b (Mathworks Inc.). The baseline 
CT scan was used as the reference volume, and spatial transformations were applied to the 
follow-up CT and PET scans.  CT images were re-sliced to the coarser voxel matrix of the 
corresponding PET scan.  This allowed direct voxel based comparison of each patient’s PET 
and CT images. 
Most of the source code for the Matlab script was created Patrick Dupont and Ilse Kant and 
adjustments were made by James Warwick.  I made further adaptations to the script and 
optimised the application procedure. 
Lung masks 
For each series of co-registered CT studies, a volume of interest (VOI) was generated as a 
lung mask (Figure 2a), using MRICro version 1.3993.  The lung mask was created on the 
overlaid CT images, using MRICro’s 3-dimensional region-growing, gradient-based tool that 
allows the user to set the origin, radius, and differences from origin and edge gradient.  This 
was combined with manual correction, since dense lesions extending into the pleura were 
often excluded from the VOI.  The lung mask excluded lung hila and main pulmonary 
vessels, but included smaller vessels.  A VOI of organs around the lungs leading that 
affected motion misregistration (usually liver, spleen and mediastinum), was created with the 
region-grow tool on the three overlaid PET scans and deleted from the lung mask (Figure 
2b).  The lung mask was then transformed to a binary image using ImageJ94 (Figure 2c). 
Background reference 
Two areas of normal lung parenchyma (NL) were selected as a reference to standardise 
uptake in each remaining lung voxels (Figure 2d).  Each NL volume consisted of spheres of 
15 mm to 25 mm in diameter that visually appeared lesion-free all on co-registered scans.  
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To enhance the representivity of the sample, the spheres were selected in opposite lungs or 
in some cases different ipsilateral lobes, depending on the distribution and extent of lung 
pathology.  The spheres were selected to exclude uptake attributed to structures 
surrounding the lung.  Images were then transformed to binary format using ImageJ.94  
 
Figure 2 Example of Volumes of interest (in red) required for quantification. 
Image Quantification 
The pre-processed series of PET/CT images were quantified using a MATLAB script 
incorporating SPM source code, developed in-house.  The script quantified disease burden 
from the PET images.  Using the mean and the standard deviation of PET counts within the 
NL volume for each study, all voxel counts within the lung mask were assigned a Z-score 
based on the formula below: 
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, in which µNL and σNL are the mean and standard deviation of PET counts within the normal 
volume for each study. 
The Z-score provided a statistical way to standardise relative intensity of FDG uptake 
throughout the lungs.  All lung voxels exceeding this Z-score threshold were defined as part 
of FDG-avid lesions.  Images of segmented lesion volumes were then exported to view 
alongside the original images for visual quality assessment.   
To determine the optimal Z-score threshold, we first processed a test set of 15 scans from 
control patients, using ascending Z-score thresholds, to minimise false positive 
segmentation.  These scans were obtained from patients undergoing PET/CT scans for non-
pulmonary clinical indications, but with lungs that were visually lesion-free on PET and CT.  
As expected, at a low Z-score threshold, the volumes segmented as abnormal in these 
healthy lungs were high, but decreased to a value close to zero for Z ≥ 8 (Figure 3).  To 
minimise false negative findings, ascending Z-score thresholds were also tested on scans 
from five PTB patients that had residual lesions with minimal or mild intensity and complex 
morphology.  Minimal intensity was defined as visually more intense than normal 
background lung parenchyma, but less intense than the mediastinal blood pool and mild 
intensity as more intense than mediastinal blood-pool, but less than the right lobe of the 
liver.83   A Z-score threshold of 8 delineated all lesions with minimal FDG-avidity, while a Z-
score of nine delineated all lesions with mild FDG-avidity, but failed to detect some lesions 
with minimal FDG avidity (Figure 4).  A cut-off of Z = 8 was thus chosen subsequently, 
based on its low false positive and false negative rates. 





Figure 3  Range, median, 25th and 75th percentiles for percentage of total lung volume classified as 
FDG-avid at different z-score thresholds. 




Figure 4 PET images 2 patients after treatment for pulmonary tuberculosis. 
Coronal (left), saggital (middle) and transverse views.  The first patient (a-c) has a residual nodule in 
the right upper lobe showing minimally increased FDG-avidity.  The second patient (d-f) has a 
complex lesion in the left upper lobe with mild FDG-avidity.  The auto-delineated metabolic lesion 
volume is overlaid using ascending Z-score thresholds, respectively at 7 (a,d) 8 (b,e) and 9 (c,f). 
Concurrently with the PET segmentation and using the same lung mask, the MATLAB script 
also segmented the CT images into 5 categories based on the density of each voxel 
compared to set values obtained from literature 75,89: 1) Low density (<-950HU),  attributed to 
cavitation or extremely hyper-inflated lung tissue (Vlow).  2)  Normal density, between -950HU 
and -500HU.  3)  Soft lesions (Vsoft), from -500HU to -300HU, usually tree-in-bud lesions or 
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nodules, but can also including normal medium to large vasculature.  4) Hard lesions (Vhard), 
above -100HU, are usually due to consolidation, cavity walls, bronchial thickening, or 
calcified fibrosis.  5)  Medium lesions (Vmedium) from -300HU to -100 HU.  This category 
should include very little normal lung tissue and usually consists of nodular infiltrates, but 
may also include hard lesions in early progression or partial resolution. 
Visual checks of the accuracy of CT lesion delineation were performed, based on these fixed 
density thresholds.  For lesions with increased density (Vsoft, Vmedium, Vhard), the segmented 
areas correlated well to lesion morphology.  However, using -950HU as the upper limit for 
low-density lesions was not specific enough for cavitation and the segmented areas in some 
cases included bullae, bronchiectasis and severe emphysema.  This necessitated an 
additional step to measure the volumes of individual cavities for each scan manually.  This 
was done using the MRICRo’s 3D region-growing tool. 
After segmentation, the program quantified the following parameters for each scan: 1) Total 
lung volume (TLV) (ml).  2) Metabolic lesion volume (MLV): the total volume of FDG-avid 
lung lesions, analogous to metabolic tumour volume in oncology patients.  3)  The mean 
intensity in the MLV divided by the mean NL volume (Zmean).  4) Total glycolytic activity index 
(TGAI):  the product of Zmean.  4) Volumes of each abnormal density category on CT, i.e. Vlow, 
Vsoft, Vmedium, and Vhard.  5) Volume with both increased metabolism on PET and abnormal 
density on CT (MLVabN).  
Re-slicing of the CT to the corresponding PET voxels allowed the program to compare CT 
density and PET intensity per voxel directly.  This is facilitated by the generation of CT 
density vs standardised PET uptake by the script.  Figure 5 shows different CT images with 
the auto-delineated metabolic lesion volume as an overlay and a scatterplot representing the 
voxels held within the lung mask. 
 The cured patient’s values (Figure 5b) move closer to normal at follow-up, while for the 
patient who failed treatment (Figure 5c), the pattern remains grossly abnormal on the density 
and intensity axes.   




Figure 5 Scatter-plots of PET/CT scans from three healthy controls and two PTB patients during 
standard treatment. 
Coronal (left), sagittal (middle) and transverse (right) views.  Y-axis shows CT density (HU), X-axis 
shows PET uptake (Z-score).  a)  Lesion-free lungs from three control patients.  b)  Dx, M1, and M6 
for a patient clinically responding well to TB treatment and showing improvement, but not resolution 
after anti-TB treatment.  c) Dx, M1, and M6 scans for a patient not clinically responding well to 
treatment and showing very little change after treatment. 
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2.7 MTB RNA extraction and detection in M6 sputum 
Sputum samples were sent to David Alland’s Laboratory in Rutgers New Jersey Medical 
School for MTB mRNA extraction and detection, as well as Xpert assays.  Shubhada Shenai 
designed and optimised the primers and conducted the experiments. 
For transcription, a QuantiFast Multiplex RT-PCR kit (QIAGEN) with a primer designed to be 
specific for each MTB target gene was used.  We selected genes that were previously 
shown to have increased expression under conditions of stress and persistence.95,96  Two ml 
sputum samples were collected and added to 2 ml of Trizol (Invitrogen), frozen and stored at 
−80°C.  Samples were not processed in a blinded fashion, but clinical outcomes were 
unknown at the time of analysis.  For RNA extraction, samples were thawed and spun down 
at 3500 g for 25 min.  The supernatant was discarded and the pellet was re-suspended in 1 
ml Trizol reagent.  The entire content of the tube was transferred into new 2 ml screw cap 
micro-centrifuge tubes containing 0.5 ml of zirconia-silica beads (diameter, 0.1 mm).  
Bacteria were disrupted in a Bead Beater (Fast Prep Cell Disrupter, FP120) using two 45 
second pulses at maximum speed of 6.5 m/sec, incubated on ice for 5 min, followed by the 
addition of 250 µl of chloroform and vigorous mixing for 15 s and then a 2–3 min room 
temperature incubation.  Samples were then centrifuged at 12, 000 g for 5 min and the upper 
clear phase transferred carefully to a new tube and mixed with an equal volume of 70% 
ethanol, applied to an RNeasy mini column (QIAGEN) and processed according to the 
manufacturer's recommendations. 
Fourteen mRNA targets (85B, dosR, hspX (acr), pstS1, carD, nuoB, tgS1, TB8.4, TB31.7, 
acpM, icL, prcA sigA, rrnAP1) were reverse transcribed, using a QuantiFast Multiplex RT-
PCR kit (QIAGEN) and a primer specific for each target gene.  The conditions for Reverse 
Transcription PCR were 50°C for 50 min, followed by 95 °C for 2 min.  The amount of cDNA 
produced was then quantified by real-time PCR with the corresponding molecular beacon.  
The 10 µl PCR reaction mixture consisted of 1X PCR buffer, 250 µM deoxynucleoside 
triphosphates, 4 mM MgCl2, 0.5 µM each primer, 4ng/µl molecular beacon and 0.03U/µl 
Jumpstart Taq polymerase (Sigma-Aldrich).  To normalise the individual reactions 6-
carboxy-x-rhodamin (ROX) was always included as passive reference dye.  PCRs were 
performed in 384-well microtiter plates in an ABI 7900 prism (Applied Biosystems, Foster 
City, CA) according to the following parameters: initial denaturation at 95°C for 1 min, 
followed by 50 cycles of: denaturation at 95°C for 30 seconds, annealing at 58°C for 30 
seconds, and extension at 72°C for 15 seconds.  PCR conditions were identical for all 
assays.  The fluorescence was recorded during the annealing step of the assay.  The 
quantity of specific target DNA was determined from the cycle threshold (CT) value with 
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reference to a standard curve of genomic DNA.  The copy numbers of target standards used 
ranged from 1 to 106 genomic copies per reaction (i.e. 10 fg to 10 ng DNA from CDC 1551 
strains).  The lower limit of detection for each of the assays was 10 fg, which is equivalent to 
1-5 copies of cDNA.  qRT-PCR reactions were performed in triplicate.  The mean of each 
triplicate are used in calculations.  The sigA target showed cross reactivity with non-
tuberculosis mycobacterial RNA at high concentrations, in addition to low-level positivity in 
four community controls and one control with other lung disease, and was subsequently 
dropped from further analysis.   
Primer sequences are listed in Appendix F. 
2.8 RNA in End of treatment bronchoalveolar lavage samples 
Culture from bronchoalveolar lavage BAL fluid is generally more sensitive than culture from 
sputum97,98, although the quality of the sample can be variable.  An additional sputum 
sample is often taken after the procedure, as the irritation of the airways leads to increased 
sputum expectoration and a high-quality sputum sample.99  Bronchoscopies were performed 
on 15 of the PTB patients within 3 months after the end of their standard treatment (EOT) 
and BAL fluid and post bronchoscopy sputa obtained.  MGIT cultures on bronchoscopy 
samples were allowed extended growth periods (12 weeks).  BAL fluid was also collected 
from 10 patients suspected of having cancer and undergoing diagnostics bronchoscopies, as 
controls.  We added 15 ml of fresh BAL samples to 30 ml Trizol and stored it at -80°C until 
RNA analysis. 
Multiplex Real Time RT-PCR Transcriptional analysis of Sputum and BAL specimens  
Fluorescence-based qRT-PCR is accepted as a gold standard for gene expression profiling 
due to its high specificity, sensitivity, accuracy and large dynamic range.  
Extraction of total RNA from BAL  
BAL samples were sent, in a blinded fashion, for MTB RNA analysis via two-step qRT-PCR 
with validated TaqMan assays developed at Stanford.100,101 The tests were conducted by 
Gregory Dolganov and Tran Van in Gary Schoolnik’s laboratory at the Department of 
Microbiology and Immunology, Stanford University School of Medicine.   
Total MTB RNA isolated from BAL was reverse transcribed using random primers and pre-
amplified in a controlled multiplex PCR with 743 MTB-specific primer sets targeting 
corresponding mRNA transcripts as described previously.102  Finally, we used only 24 gene-
specific TaqMan assays for individual gene transcript quantification of multiplex PCR 
products targeting the genes shown as differentially regulated in stress or persistence based 
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on available literature. 95,96 These genes included recF, eccD3, menA, pabC, accD3, iprB, 
Rv1421, gabD2, Rv1910c, hspX, lipX, fadD9, tgs1, fadE34, Rv3675, sodA, trxB2, rpsJ, rplV, 
sigI, Rv1255c, sigB, sigH, rpsK.95  
Samples were thawed and total RNA was extracted using a glass matrix tube for cell lysis 
(Lysing Matrix B, Q Biogene) in a FastPrep FP120 instrument (Bio 101, Thermo Savant) with 
a speed setting of six for three iterations of 30 s, with cooling on ice for 1 min after each 
iteration.  After processing, chloroform was added, followed by separation of the aqueous 
and organic layers.  The aqueous phase containing the RNA was removed to a fresh tube 
and the RNA was precipitated overnight at -20°C after addition of glycoblue (Ambion), 0.1 
volume of 5 M ammonium acetate, and an equal volume of isopropanol were added.  The 
resulting RNA pellet was re-suspended in 50 µl of RNase free H2O and cleaned by three 
rounds of the RNeasy® mini column system, interspersed with off-column DNase treatments 
(Promega RQ1 DNase).95   
Genome Expression Profiling of MTB was performed using Two-Step Multiplex RT-PCR.  
The protocol below consists of three parts: 1) First strand cDNA synthesis and Controlled 
Multiplex Pre-Amplification of cDNAs; 2) Preparation of Primer and Probe Sets; and 3) 
Individual qRT-PCR (Taqman) quantification of Amplified cDNAs using LightCycler480. 
Each RNA sample (5 µl) was taken into two separate first strand cDNA synthesis reactions 
(RT+ and RT-) to control for DNA contamination.  An additional water control (zero RNA) 
was also added.  To each sample, 0.5 µl Exo-resistant Random Primer (Fermentas S0181), 
1 µl 10mM dNTPs (Fermentas R0193) and 3.5 µl Nuclease Free Water (Ambion AM9938) 
were added for a total of 10 µl.  This mix was incubated for 3 minutes at 70 ◦C in a thermal 
cycler, and then placed on ice.  
During this incubation, two cocktails were prepared:  one containing reverse transcriptase 
(RT+) and one without (RT-).  Each RT+ cocktail contained 4 µl 5X Maxima RT Buffer 
(Fermentas EP0741), 0.5 µl Ribolock RNase-Inhibitor (Fermentas EO0382), 0.5 µl Maxima 
RT enzyme (Fermentas EP0741), and 3.0 µl Nuclease Free Water for a total of 10 µl.  The 
RT- cocktail was the same, except water was substituted for the RT enzyme.  These 
cocktails were scaled up for multiple samples and 10 µl aliquots were added to each RT+ or 
RT- sample prepared above.  The samples were mixed gently and then gently centrifuged 
for 2 min.  They were incubated at 50 °C  1 hour, 95 °C  2 minutes (to inactivate the reverse 
transcriptase), then stored at 4 °C.  Maxima Reverse Transcriptase (RT) possesses an RNA 
and DNA-dependent polymerase activity as well as RNase H activity.  
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qRT-PCR on pre-amplified material: All outflanking primers and TaqMan probe sets had 
been validated in multiplex PCR pre-amplification for linearity of amplification using all the 
genes used in each pre-amplification cocktail.  We also validated all individual TaqMan 
assays from our collection for sensitivity and linearity before we started using them in gene 
expression profiling.  A complete database with all available validated TaqMan primer sets 
used for pre-amplification available at ftp://smd-ftp.stanford.edu/tbdb/rtpcr/taqman_oligos.fa. 
Sequences and design of specific PCR primer/probe sets shown in Appendix F. 
Primer and probe qRT-PCR sets for each gene consist of a forward primer (TMF), a 
FAM/BHQ-labelled probe (TMP), and a reverse primer (TMR).  These were ordered from 
Biosearch at a 100 uM concentration and a Taqman Mix was prepared for each gene.  
Twenty-seven µl of the forward primer, 27 µl of the reverse primer, and 9 µl of the probe 
were mixed in 1737 µl of Nuclease Free water for a total of 1800 µl.  This resulted in a 
dilution of the forward and reverse primer to 1500 nM and the probe to 500 nM.  We used 2 
µl of this mix in a 10 µl qRT-PCR, resulting in a final reaction concentration of 300 nM for 
each primer and 100 nM for the probe.   
Two different water controls were run throughout the process: one starting at the cDNA step 
and one starting at the amplification step.  All RT- controls were negative, but water controls 
for pabC, accD3, lipX, Rv1255c and sigB showed some reactivity and these targets were 
excluded from further analysis.  Additionally, two samples of 104 gene copy number H37Rv 
genomic DNA were amplified in each amplification mix and run on each plate.   
Genomic Equivalent DNA calculation 
We isolated genomic DNA by buffer extraction from the interphase after MTB lysis with 
Trizol.  DNA was pre- amplified with 24 genes and individual TaqMan assays quantified the 
amplicons.  Median Ct was calculated for 24 genes for each sample and compared to 
genomic DNA reference to calculate GE.100  
Statistical analysis 
As this was an observational study, we did not apply randomisation.  The calculated sample 
size of the cohort was intended to provide a representative range of biological reactions 
during a favourable response to PTB treatment.  We performed bronchoscopies and EOT 
+1y PET/CT scans on all consenting patients who have not passed the time point when 
ethical approval was obtained for this amendment to the protocol.  Analysis was either 
performed blinded (BAL) or outcomes were not known at the time (M6 sputum mRNA and 
Xpert; M6 PET/CT scans). 
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For analysis in chapter 3: 1) Clinical and microbiological parameters of failed treatment and 
recurrent outcome groups were compared to the cured group using a two-tailed, unpaired 
Student's t-test – that I performed with Statisticatm Version 12.  2) Associations between 
categorical variables were evaluated using the Fisher Exact Test for independence, the Chi-
squared Test for trend in proportions and the Asymptotic independence test in R version 
3.2.2 by Prof Gerard Tromp.  3)  Principal component analysis was performed by Prof 
Tromp, using the singular value decomposition approach (prcomp in R version 3.2.2), to 
derive a limited set of variables (principle components; PC) that captured the variance in the 
mRNA values.  Matrices of Ct values for each mRNA species in each patient were used as 
input for the analysis.  The first PC captured more than 80% of the mRNA variance in the 
analyses and was used to represent the mRNA data for each individual with a single value.  
Figure 12  and Figure 13 contains box and whisker plots of the arcsinh-transformed first 
principal component of mRNA transcript PCR data.   
For analysis in chapter 5:  1)  Tom Peppard and Yookwan Noh performed statistical analysis 
and created graphical representations regarding correlations between scan parameters and 
time to culture negativity groups.  The PET and CT values were log transformed and 
subjected to analysis of variance.  2)  Tom and Yookwan also created receiver operating 
curves for a failed treatment outcome and the associated Mann-Whitney U-test P-values, the 
distance to unity and the level of informedness.  3) Correlation matrices were created by 
Tom Peppard.  4)  Optimal thresholds for prognostic criteria of pooled unfavourable outcome 
were set after I performed analysis of distribution (Statistica), receiver operating curves 
(Prism Graphpadtm software) and also performed some rounding of values.  5)  I entered the 
results of the criteria of contingency tables and calculated sensitivity, specificity, negative 
predictive value, positive predictive value and relative risk using Prism Graphpad software.  
6)  I calculated associations and between PET/CT variables and clinical and microbiological 
factors and prepared graphical representations in Statisticatm version 13.  Test performed 
include Fisher Exact test for categorical variables, correlation coefficients for continuous 
variables and two-tailed, independent student’s T-tests for grouped continuous variables.  
We also report the results for Levene's test for equal variance.  Since most of the variables 
showed a mild positive skew, I also performed Mann-Whitney U-test for independent 
samples.  As a rule, there was good cohesion between the parametric and non-parametric 
testing. 
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3. Results: Persistent lesions and MTB mRNA detected after 
treatment 
3.1 Patient demographics and treatment outcome 
Ninety-nine HIV-uninfected, non-diabetic, adult patients with PTB were recruited at diagnosis 
and followed up during treatment in Cape Town, South Africa.  This included 39 patients with 
one or more previous episode of PTB, more than one year prior to recruitment.  Ninety-five 
patients had DS strains.  Of these, 72 received a standard, 6-month regimen, while 23 
received an extended regimen of 8 months [22 due to previous episode(s) of TB and one 
due to delayed smear conversion].  Two patients had INH mono resistant TB and were 
treated for six and 12 months respectively and two patients with multi-drug resistant (MDR) 
TB were treated for 2 years on individualised regimens.  Month 6 (M6) was selected as a 
fixed time-point for PET/CT and sputum collection, consistent with current WHO treatment 
guidelines.14   
Of the 99 patients, 8 remained sputum culture positive at M6 and failed treatment, 76 culture 
converted and maintained cure and 12 initially culture converted, but were diagnosed with 
recurrent (due to relapse or reinfection) PTB within 2 years after treatment completion (EOT 
+ 2y).  Initial treatment outcome was un-evaluable (UE) for three patients due to 
contaminated cultures.  All extended treatment patients maintained an unchanged sputum 
culture status between M6 and EOT. Fourteen patients took fewer than approximately 80% 
of their treatment dosages during the 6-month period, which is regarded as poor adherence 
in most clinical trial designs.4,6  The failed treatment group included 4 patients with poor 
treatment adherence and 1 with MDR disease. Most patients (96%) reported symptomatic 
improvement during treatment, but residual symptoms or signs were often encountered at 
the end of treatment. The most frequent were coughing (47), dyspnoea (21) and low body- 
mass index (24).   
Table 1 provides a summary of patient demographics, treatment adherence, as well as 
culture and GeneXpert MTB/Rif (Xpert) results.  
Table 1: Clinical and microbiological parameters for PTB patients 
  All (n=99) Cured (76) Failed (8) 
Recurrence 
(12) 
Age 31 (17 -66) 32 (17-64) 29 (18-66) 34 (21-52) 
Male (n) 60 (60%) 49 (82%) 5 (63%)  8 (67%) 
Previous PTB 39 (39%) 20 (27%) 4 (50%) 4 (33%) 
Poor adherence 14 (10%) 9 (12%) 4* (50%) 1 (8%) 
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MDR 2 (2%) 1 (1%) 1 (12.5%) 0 (0%) 
M6 Xpert positive (n) 30 (30%) 16 (22%) 7 (88%) 6 (50%) 
Smoker (n) 77 (78%) 56 (74%) 6 (75%) 12 (100%) 
Dx Body Mass Index 18 (13.1 -42) 18 (13.1-23) 17 (16.7-23) 19* (16.3-42) 
M6 Body Mass Index 18 
(14.5 - 
43) 
19 (14.5-25) 19 (17.2-26) 19* (17.5-43) 
Time to Negativity (weeks)   8 (0.2-24) 8 (1-24) >24*   8 (0.3-12) 
Summary of median (range) or number (%) of clinical and microbiological parameters for PTB 
patients.  The asterisk (*) in the Failed and Recurrence columns indicate a significant difference from 
cured values (two-tailed, non-paired, Student's T-test; P-value < 0.05).  Poor adherence refers to 
patients that missed more than 20% of their treatment (note: only three of these patients met WHO 
criteria of treatment default). 
Of the recurrent PTB patients, two were culture confirmed; five were confirmed by both Xpert 
with supporting acid fast bacillus (AFB) testing for smear positivity by direct microscopy; 
three were Xpert negative at month 6, but converted back to positive; and two remained 
Xpert positive for more than 6 months, but complained of increased symptoms.  None of the 
un-evaluable group was diagnosed by healthcare providers with recurrent PTB before EOT 
+ 2y.   
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Table 2 shows a summary of the time from end of treatment (EOT) to re-diagnosis and the 
supporting results - the asterix indicates results at the time of re-diagnosis.   
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S22 Neg Neg Positive n/a n/a Positive* Neg 15 Late, Definite 
S34 Neg  Pos n/a Pos* Neg Contaminated Neg 9 
Early, Moderate 
evidence 
S88 Neg  Neg n/a Pos* Neg Negative* Pos* 12 
Early, Strong 
evidence 
S93 Neg  Neg n/a Pos* N/a Negative Neg 18 
Late, Strong 
evidence 
S95 Neg  Pos n/a Pos* Neg Negative Pos 10 
Early, Moderate 
evidence 
S101 Neg  Pos Contaminated Pos* Pos* Contaminated Neg 17 Late, Definite 
S112 Neg  Neg n/a Pos* Pos* Contaminated Pos 3 Early, Definite 
S130 Neg  Neg n/a Pos* Neg Negative Neg 17 
Late, Strong 
evidence 
S137 Neg  Pos n/a Pos* Pos* Negative Pos 5 Early, Definite 
S140 Neg  Pos n/a Pos* Pos* Negative Neg 5 Early, Definite 
S142 Neg  Pos n/a Pos* Pos* Negative Pos 17 Late, Definite 
S152 Neg  Neg Positive Pos* Neg Positive Pos 3 Early, Definite 
 
Spoligotyping was performed on sputum cultures at diagnosis. Spoligotyping was 
unsuccessful in 10 patients.  The Beijing strain clade was, by far the most prevalent strain 
and found in the culture of 51 (57%) of PTB patients (Figure 6).  This was followed by LAM 
and LCC strains.   
 
Figure 6  Frequency of strain clades cultured from sputum at Dx for South-African cohort. 
Spoligotyping was also performed at M6 for patients that failed treatment.  In 6 of the 8 
cases identical strains were found, while the remaining 2 patients had different strains at Dx 
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and M6.  This may be due to reinfection during the treatment phase, or concurrent infection 
with different strains from Dx – previously reported in 19% of patients in Cape Town.103 
We also performed qualitative analysis of PET/CT images from 14 HIV-negative patients 
with PTB in Masan, South Korea.  They included three MDR cases and two with mono-
resistance to rifampicin.  Twelve were cured (culture converted within 6 months), one had 
un-evaluable outcome and one was diagnosed with culture confirmed recurrence after initial 
cure.  In this case  a strain was cultured on sputum different to the strain at diagnosis, 
suggesting reinfection.  Study design and research procedures are detailed in Figure 1c.   
3.2 Month 6 PET/CT findings in 99 South African patients 
All patients had 18F-FDG PET/CT lung scans at Dx, month 1 (M1), and M6 of TB treatment.  
Comparing M6 to Dx scans we identified three distinct response patterns: 1) Resolved, 2) 
Improved and 3) Mixed.  A resolved response pattern refers to minimal or no increased FDG 
uptake compared to surrounding healthy tissue, regardless of structural abnormalities on CT.  
Improved scans had decreased intensity of all lesions compared to the baseline scan, but 
still one or more lesion(s) with increased uptake compared to background and reference 
structures.  Mixed responses showed at least one new FDG-avid lesion or at least one lesion 
with increased FDG uptake (intensified) compared to the baseline scan.  Representative 
cases are shown in Figure 7. 
Surprisingly, only 14 (14%) patients had a resolved pattern on their M6 scan (Figure 7a) and 
in 51 (52%) we found an improved response on M6 scan (Figure 7b).  A mixed response 
was seen in 34 (34%) patients (Figure 7c), of which 14 had both new and intensified 
lesion(s), 16 had only intensified lesion(s) and 4 had only new FDG-avid lesion(s).  
The morphology associated with the most intense lesion of each mixed and improved M6 
scan included features suggestive of active PTB, such as cavities (found in 26 cases), 
patchy consolidation (in 22), complex lesions involving consolidation with cavitation (16), 
nodular infiltrates (17), enlarged hilar lymph nodes (3) and pleural based infiltrates (1).  
Treatment outcome was associated with scan response pattern, (Figure 9a; p < 0.01) with a 
mixed response found in all failed patients.  Neither a mixed response nor a high maximum 
lesion intensity, however, was specific to a poor outcome and 21 (28%) of cured patients 
had a mixed response, while 55 (72%) still had M6 lesions with moderate to very high 
intensity, which would be compatible with the intensity range found at Dx.   




Figure 7  PET/CT images at Dx, M1 and M6 for representative cured patients after 6 months of 
standard treatment. 
3-dimensional anterior (top panels) and transverse views, at the level of blue lines, (lower panels).  (a) 
Resolved scan, without residual abnormal FDG uptake, some structural abnormalities remain on CT 
scan.  (b) Improved scan, where all lesions have improved since diagnosis, but abnormal CT lesions 
and increased uptake persist.  This example includes thick-walled cavities with high FDG uptake.  (c) 
Mixed scan response with either new FDG-avid lesions or increased intensity of some lesions.  This 
example shows a large new FDG-avid nodule with high intensity uptake in the left lung upper lobe. 
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3.3 PET/CT findings in 14 South Korean patients 
All 14 patients had PET/CT scans at Dx, M1 and M6.  We applied the same criteria as above 
and found 7 mixed (50%), 6 improved and only 1 resolved M6 scans.  Eleven had moderate 
to very high intensity lesions at M6.  Figure 9b shows a summary of scan findings; detailed 
demographical data in Appendix C and representative images in Figure 8. 
 
Figure 8  PET/CT images for representative cases at Dx and M6 from South-Korean cohort.   
3-dimensional anterior (top panels) and transverse views, at the level of blue lines (lower panels), of 
Cases included in this group are all diagnosed with drug-sensitive TB strains and cured (culture 
negative) after 6 months of standard treatment a) Mixed response pattern with old cavity, becoming 
consolidated and more intense.  b)  Mixed response pattern with new patch of consolidation. c)  
Improved scan with nodular infiltrates becoming smaller, but still maintaining moderate intensity. 




Figure 9 Clinical outcome and associated M6 PET/CT scan findings.   
(a) South-Africa: Clinical outcome and associated M6 scan response pattern.  Mixed scan responses 
were more likely to have an unfavourable outcome (Fisher exact test, two-sided: P = 0.002). Data per 
patient in Appendix A.  (b) South Korea: Patients grouped into those diagnosed with MDR strains or 
with drug-sensitive or rifampicin mono-resistant (Rif-mono) strains.  All MDR cases culture converted 
within 6 months, while the DS/Rif-mono group includes nine cured, one un-evaluable and one 
recurrent patient. Data per patient in Appendix C. 
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3.4 PET/CT findings 1 year after completion of treatment  
In view of the findings in the M6 scans we added a fourth scan, 1 year after the end of 
treatment (EOT + 1y) for 50 South-African patients who had not yet passed this time-point 
and who were cured at M6.  Eight of these 50 patients were diagnosed with recurrent 
disease by healthcare providers within two years of treatment completion, five before the 
EOT + 1y scan and three subsequently.  The other 42 maintained cure. 
When the EOT + 1y scans were compared to the M6 scans, there was improvement in size 
and intensity of most residual lesions.  However, only 32% of EOT + 1y scans were 
completely resolved.  The remaining 68% had significant residual lesion(s), half of which had 
improvement of all lesions and the other 34% a mixed lesion response compared to the M6 
scan.  Morphology of new FDG-avid lesions at EOT + 1y included nodular infiltrates (found 
in four cases), hilar lymph nodes (in 1 case), cavitation (2), consolidation (2), or lesions with 
combined morphology (3).  Residual M6 lesions showing similar or more intense FDG 
uptake at EOT + 1y included consolidation (2), cavitation (4) and nodules (2).  Examples of 
EOT + 1y scan progression can be seen in Figure 10.  All three patients who developed 
recurrent PTB after EOT + 1y had mixed scan outcomes at this time-point, while none with 
resolved scans was diagnosed with recurrence (Figure 11).  




Figure 10  Dx, M6 and EOT + 1y PET/CTs for 3 representative patients after 6 months of treatment.   
3-dimensional anterior and transverse slices at the level of horizontal blue line.  a) A large new FDG-
avid nodule in right lung apex lesion develops by M6 but, improves over the next year, with some 
residual increased FDG uptake. b) Bilateral upper lobe cavities improve during treatment, but nodules 
with normal FDG-uptake at M6 develop new cavitation and increased uptake by EOT + 1y.  c) Multiple 
lesions with continuing improvement of FDG-avidity at M6 and EOT + 1y but with a large new area of 
consolidation at EOT + 1y. This patient was Gene Xpert positive, but culture negative at the time of 
EOT + 1y scan, but diagnosed with recurrent disease 6 months later (18 months after treatment 
completion), while patients a) and b) maintained cure. 




Figure 11  Clinical outcome and associated PET/CT scan findings 1 year after the end of successful 
PTB treatment (EOT + 1y). 
Patients are grouped based on whether they remained free from PTB or diagnosed with recurrent 
disease within 2 years after the end of treatment.  The patients with a recurrent PTB episode are also 
divided into those that received re-treatment before or after the EOT + 1y scan.  EOT + 1y scans were 
compared to corresponding M6 scans and categorised as Mixed, Improved or Resolved.  Lesion 
intensity ranking categories are shown in bottom row of boxes for the respective response patterns.  
Data per patient supplied in Appendix B.  Due to rounding of percentage values totals may equate to 
99% or 101%.   
3.5 DNA and mRNA in M6 sputum 
Patients with an Xpert positive M6 sputum were more likely to have an unfavourable clinical 
outcome (7/8 failed treatment, 6/12 recurrent and 16/65 cured; p < 0.001) and M6 PET/CT 
lesions with high to very high intensity (P = 0.04).   
mRNA detection assays were performed on M6 sputum from 75 consecutive participants (60 
cured, 4 failed treatment, 9 recurrent and 2 un-evaluable) who produced adequate volume 
sputum, as well as on sputum from 20 community controls and 5 controls with lung disease 
other than TB (OLD).  13 MTB-specific mRNA targets [85B, dosR, hspX (acr), pstS1, carD, 
nuoB, tgS1, TB8.4, TB31.7, acpM, icL, prcA and rrnAP1] were assayed.  
Among the 75 patients' M6 sputum, at least one MTB mRNA target was detected in 29 
(39%): 22 (37%) of the cured, 4 (100%) of the failed treatment, 2 (22%) of the 9 recurrent 
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PTB and 1 of the un-evaluable outcome patients.  The most frequently detected transcripts 
were hspX (Acr), acpM and rrn, respectively present in 20, 17 and 12 patients’ M6 sputum.  
Tgs1 and acpM transcripts were detectable at low levels in one community control each.  
We performed principal component analysis (PCA) to reduce the dimensions of all transcript 
levels into one variable that indicated mRNA presence.  PCA results in Figure 12 illustrate 
that all cases with failed treatment and 22 cured patients still had detectable MTB mRNA in 
their M6 sputum.  Two community controls and no controls with other lung disease had low 
levels of mRNA transcripts (p = 0.001).  There was a trend for patients with very high M6 
PET/CT lesion intensity to have MTB mRNA in M6 sputum and patients with no significant 
M6 scan uptake to be sputum mRNA-free (P = 0.08).  
 
Figure 12  Box and whisker plots of the transformed PC1 of mRNA transcript PCR data 
Principal component one (arcsinh); derived from principal component analysis (transcript copy 
numbers for each patient supplied in Appendix D), demonstrating separation by detectable MTB 
mRNA as captured in PC1.  M6 sputum from 75 PTB cases by clinical category; 22 of 60 cured 
cases, all 4 failed treatment cases and 2 of the 9 recurrent cases in the group have detectable MTB 
mRNA in their sputum. None of the other lung disease participants and two of 20 healthy community 
controls have detectable MTB mRNA (p < 0.01).  
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3.6 RNA in end of treatment bronchoalveolar lavage samples 
We obtained bronchoalveolar lavage (BAL) from the most affected lung segment identified 
on PET/CT as well as post-bronchoscopy sputa from 15 consecutive, consenting patients 
with DS PTB within 3 months after EOT.  Treatment duration was 6 months for this group. 
We also collected BAL fluid in 10 control patients undergoing bronchoscopy as part of 
clinical workup for suspected lung cancer.  The 15 EOT patients included 13 cured (M6 
culture negative), 1 recurrent (M6 culture negative, but converted back 3 months after 
treatment) and 1 failed treatment (M6 culture positive) case.  The 10 controls included one 
patient in whom new active PTB was subsequently diagnosed on BAL culture (although 
sputum culture was negative).  All other BAL and post-bronchoscopy sputa were negative for 
MTB in liquid culture.  Cancer was confirmed in 5 controls, while 3 controls had bacterial 
infections and one had interstitial fibrosis.  Five of these controls had a positive 
Quantiferon® blood test (suggesting latent TB infection). Xpert was positive on BAL or post-
bronchoscopy sputum at EOT for 10 of the 15 PTB cases and the new PTB case and MTB 
DNA was detected in all EOT BAL samples by qRT-PCR. 
Blinded mRNA detection assays were performed on all BAL samples.  19 MTB-specific 
mRNA targets (recF, eccD3, menA,  iprB, Rv1421, gabD2, Rv1910c, hspX,  fadD9, tgs1, 
fadE34, Rv3675, sodA, trxB2, rpsJ, rplV, sigI,  sigH and rpsK) previously shown to be 
differentially regulated in stress or persistence95,96 were assayed.  
A median of 8 mRNA transcripts were positive in the BAL from EOT cases (range 1-19); one 
MTB mRNA transcript was detected in BAL from 3 of the 5 Quantiferon® positive control 
cases (EOT vs controls p < 0.001).  The target most frequently detected was hspX, present 
in the treatment failure and new diagnosis cases, as well as in 14 of the cured patients, but 
none of the controls. The newly diagnosed PTB case (from the control set) had 5 transcripts.  
We used PCA to summarise mRNA positivity (Figure 13 shows principal component 1 in and 
Appendix D provides transcript values per patient). 




Figure 13 Box and whisker plots of the transformed PC1 of mRNA transcript PCR data 
Principal component one (arcsinh); derived from principal component analysis demonstrating 
separation by detectable MTB mRNA as captured in PC1 for End of treatment (EOT) bronchoalveolar 
lavage fluid by clinical category.  The new PTB case and 15 EOT cases (1 failed treatment, 1 
recurrent and 13 cases that maintained cure), all still have significantly detectable mRNA.  Three of 
the 6 Quantiferon® positive controls show inconclusive levels of MTB mRNA, whereas the 
Quantiferon® negative controls have no detectable MTB mRNA (P < 0.001). mRNA values per case 
in Appendix D. 
3.7 Statistical Associations between grouped variables 
The aim of the analysis was to test which clinical, imaging and microbiological factors had 
either meaningful or confounding associations. 
3.7.1 Scan response patterns and clinical outcome 
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Table 3  Cross tabulation of clinical outcome and scan response pattern 
 Mixed Improved Resolved 
Cure 21 43 12 
Recur 4 7 1 
Fail 8 0 0 
 




Figure 14  Association between clinical outcome and scan response pattern. 
The size of the dots represent observation frequencies.  The blue line shows the linear fit and the 95th 
confidence interval. 
 
To perform the proportion trend test, we pooled failed and recurrent treatment groups into 
unfavourable. 
Table 4  Association between scan response pattern and collapsed clinical outcome 
 Cured Unfavourable 
    Mixed 21 12 
    Improved 43 7 
    Resolved 12 1 
 
 Chi-squared Test for Trend:  p-value = 0.009 





The data in the contingency tables (Table 3,Table 4) are clearly not independent by the 
Fisher exact test (P < 0.004 with or without the unevaluable class). There is a good 
correlation (trend; Figure 14) between scan score and clinical outcome, with a P < 0.01 for 
the Cochran-Armitage trend test when the clinical outcome is collapsed into favourable and 
unfavourable outcomes.  
 
The same trend is shown in the graphics where clinical outcome and scan score are ranked 
ordinally. The linear fit for the graphic data is inappropriate (diagnostics show a poor fit for 
the QQ-plot, many points with high leverage and large distance); nevertheless, the graphics 
show the weighted trends more effectively than the unweighted proportions against the 
ranks of scan scores. 
 
3.7.2 M6 Sputum Xpert and outcome 
        
Table 5  Association between clinical outcome and M6 Xpert result. 
 Xpert Negative Xpert Positive 
Cure 59 16 
Recur 6 6 
Fail 1 7 
   
        Fisher's Exact Test: p-value = 0.0002 
There is a clear association between M6 xpert positivity and an unfavourable outcome 
(Table 5).  A positive M6 Xpert implied a relative risk of unfavourable outcome of 4.2, with a 
sensitivity of 0.65 and a specificity of 0.79. 
3.7.3 M6 Sputum mRNA vs Outcome & Diagnosis 
Table 6  Association between clinical status and sputum MTB mRNA. 
       Positive Negative 
  Fail 4 0 
  Recur 2 7 
  Cure 23 29 
  Community Controls 2 18 
  Other Lung Disease Controls  0 5 
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  Fisher's Exact Test:  p-value = 0.0006 
While the mRNA status and clinical status are not independent of each other, the distribution 
of the data (Table 6) is not what is expected given the marginal totals.  If the data were 
distributed randomly (e.g., equal chance of being positive or negative) the P-value would be 
unremarkable. 
 
The data do not permit testing for a trend as there is no reasonable ordering of diagnostic 
classes. Collapsing all TB into one class and all controls into another (Table 7), the trend test 
will approximate the Fisher test, i.e., a test of non-random distribution.  
            
Table 7 Association between collapsed clinical status compared to sputum MTB mRNA. 
 Positive Negative 
  EOT TB 29 36 
  Control 2 23 
 
        Asymptotic General Independence Test: p-value = 0.001. 
        Fisher's Exact Test for Count Data: p-value = 0.001. 
 
Detection of MTB mRNA was significantly more likely in patients at end of treatment, 
compared to controls.  
3.7.4 Broncho Alveolar lavage mRNA vs Outcome & diagnosis 
Considering the RNA in BAL, ordinal arrangement of diagnosis make somewhat more 
sense. One could consider the worst condition to be failure, next worst newly diagnosed and 
untreated TB, then end-of-treatment TB (successfully treated recently ill with TB), and then 
controls. Among controls, there is a distinction between latently infected controls and Mtb-
free controls. A surrogate marker is Quantiferon status, positive indicating exposure to TB 
and likely latently infected. This is shown in Table 8.                 
Table 8 Association between clinical TB status and BAL MTB mRNA. 
 mRNA Positive mRNA Negative 
  Fail 1 0 
  New TB 1 0 
  EOT TB 14 0 
  QFN+ Other Lung Disease 3 3 
  QFN- Other Lung Disease 0 3 
 
The Cochran-Armitage trend test then yields the following: 
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        Asymptotic General Independence Test: p-value = 0.0028 
 
Using a linear models implementation of the Cochran-Armitage trend test: 
       Chi-squared Test for Trend in Proportions: p-value = 0.0003 
 
We also tested the trend for all TB (collapsing the single failure and newly diagnosed TB into 
the EOT TB) against the controls stratified by quantiferon status (Table 9).  This reduced the 
degrees of freedom.                   
Table 9 Association between collapsed clinical status and BAL MTB mRNA 
 mRNA Positive mRNA Negative 
NEW & EOT PTB 16 0 
QFN+ Other Lung Disease 3 3 
QFN- Other Lung Disease 0 3 
 
Using a linear models implementation of the Cochran-Armitage trend test: 
        Asymptotic General Independence Test: p-value = 0.00032 
Note that using this implementation we can collapse groups by assigning them the same 
“score” or category. 
        Chi-squared Test for Trend in Proportions: p-value= 4.2 x 10-5 
        Fisher's Exact Test:  p-value = 0.0002 
3.7.5  Adherence, Smoking, Previous PTB vs outcome  
Table 10  Association between clinical outcome and whether patient took >80% of doses 
 Good adherence Poor adherence 
Cure 69 7 
UE 1 2 
Fail 4 4 
Recurrent 11 1 
 
   The Pearson's Chi squared test for independence:  P-value = 0.0066  
This showed that the data (Table 10) is not independent, however, no non-linear trend or 
correlation were found. 
 
When we collapsed the Outcomes into favourable (cured) and Unfavourable (Failed and 
Recurrent) and excluded Unevaluable, no association was found. 
   Fisher Exact test:  P-Value =  0.12006 




Table 11  Association between smoking status and collapsed clinical outcome 
 Smoker Non-Smoker 
Cure 56 20 
Unfavourable 18 2 
 
     Fisher Exact Test: P-Value 0.147  
No significant association was found between smoking status and clinical outcome (Table 
11). Note that non-smokers were underrepresented in our PTB patient cohort. 
Table 12  Association between collapsed clinical outcome and previous PTB episodes  
 1st episode Previous PTB 
Cure 54 22 
Unfavourable 12 8 
 
   Fisher Exact Test: P-Value = 0.418 
No significant association was found between clinical outcome and previous PTB episodes 
(Table 12).   
3.7.8  Gene Xpert and M6 PET/CT scan         
Table 13  Association between grading of most intense M6 PET lesion and M6 sputum Xpert. 
 Xpert Negative Xpert Positive 
Very High 5 5 
Moderate - High 52 22 
Minimal 11 3 
 
    Fisher's Exact Test: p-value = 0.3031 
 
Table 14  Association between M6 PET/CT response pattern and M6 sputum Xpert. 
 Xpert Negative Xpert Positive 
Mixed 19 14 
Improved 38 13 
Resolved 11 3 
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   Fisher's Exact Test:  p-value = 0.1963. 
No association was found between the grading of most intense M6 PET lesion and M6 
sputum XPert positivity (Table 13), or between M6 PET/CT scan response pattern and Xpert 
positivity (Table 14). 
3.7.8  M6 Sputum mRNA and M6 PET/CT scan  
Table 15  Association between grading of most intense M6 PET lesion and M6 sputum Xpert 
 Xpert Negative Xpert Positive 
Very High 2 5 
Moderate - High 37 23 
Minimal 7 1 
 
Fisher's Exact Test p-value = 0.08077 
We noted a trend for patients with very high intensity lesions to be more likely to have M6 
sputum positive for XPert and mRNA and for patients with resolved scans to have no mRNA 
in M6 sputum (Table 15). 
3.7.9 Adherence and M6 PET/CT scan  
Table 16  Association between grading of most intense PET lesion and whether patient took > 80% of 
TB doses. 
 Good adherence Poor adherence 
Very High 8 2 
High 37 4 
Moderate 19 4 
Mild 10 1 
Minimal 9 1 
None 2 2 
 
        Fisher's Exact Test: p-value = 0.3248 
        Chi-squared Test for Trend in Proportions: p-value = 0.4279 
 
There is no trend suggesting that adherence leads to detectably more intense lesions (Table 
16).  
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Table 17 Association between adherence groups and scan response pattern. 
Scan response pattern Good adherence Poor adherence 
Mixed 26 8 
Improved 48 3 
Resolved 11 3 
 
        Fisher's Exact Test:  p-value = 0.03621 
        Chi-squared Test for Trend in Proportions: p-value = 0.3472 
 
There was no trend suggesting that adherence leads to detectably different scan outcomes 
(Table 17); although the groups seem to differ (non-adherence is not independently 
distributed among the groups).  The Spearman correlation is 0.115, weak to no correlation. 
  
Table 18 Association between adherence groups and M6 scan response pattern. 
Scan response pattern Good adherence Poor adherence 
Mixed 26 8 
Improved/Resolved 59 6 
 
        Fisher's Exact Test:  p-value = 0.06986 
 
There was no significant evidence for association and a weak Spearman correlation of 0.19 
for adherence resulting in better (improved/resolved) outcomes (Table 18). 
3.7.10  M6 Xpert and M6 mRNA positivity  
Table 19  Association between M6 sputum MTB mRNA and Xpert positivity. 
 Xpert Negative Xpert Positive 
mRNA Negative 35 10 
mRNA Positive 21 8 
 
Fisher's Exact Test:  p-value = 0.78198 
 
There is no significant association between positivity of mRNA and Xpert in M6 sputum 
(Table 19). 




3.7.11  Poor adherence and Xpert positivity 
 
Table 20  Association between M6 Sputum Xpert positivity and whether patient took >80% of doses. 
 Good adherence Poor Adherence 
Xpert Negative 62 6 
Xpert Positive 22 8 
 
        Fisher's Exact Test:  p-value = 0.02882 
        Chi-squared Test for Trend in Proportions:  p-value = 0.01999 
       Spearman correlation: 0.235008 
 
We found a signicant trend suggesting that poor adherence leads to M6 sputum Xpert 
positivity, in spite of the weak Spearman correlation of 0.24.  The trend is supported by the 
Fisher test showing an association (Table 20).  
 
Table 21 Association between M6 Sputum MTB mRNA positivity and whether patient took >80% of 
doses. 
 Good adherence Poor adherence 
mRNA Negative 40 6 
mRNA Positive 26 3 
 
        Fisher's Exact Test: p-value = 1 
        Chi-squared Test for Trend in Proportions: p-value = 0.7262 
 
There was no evidence of non-independence between adherence and Mtb RNA presence 
(Table 21) and there is essentially no correlation (Spearman correlation of 0.04).   
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3.7.12  mRNA Copy number rank correlation 
Table 22  Ranked mRNA transcript, on copy number in BAL from failed treatment case. 
 S163 S139 S141 S144 S145 S146 S150 S153 S154 S155 S159 S161 S162 Mean 
Mtb Gene Fail Cure Cure Cure Cure Cure Cure Cure Cure Cure Cure Cure Cure Cure 
hspX 1 5 19 4 3 8 1 5 1 1 3 1 4 4.58 
sodA 2 19 19 1 7 19 19 19 19 19 1 19 19 15 
rpsK 3 2 5 19 1 4 19 19 5 19 19 4 5 10.08 
rpsJ 4 1 6 7 2 2 19 2 4 19 2 2 9 6.25 
lprB 5 4 2 3 12 1 19 3 19 2 6 19 6 8 
tgs1 6 19 19 2 19 5 19 19 19 19 4 19 3 13.83 
eccD3 7 7 19 5 8 9 19 19 19 19 7 5 19 12.92 
trxB2 8 6 1 9 19 3 19 19 19 19 5 19 11 12.42 
Rv3675 9 3 3 6 9 19 19 1 2 19 8 3 1 7.75 
rplV 10 19 7 11 11 11 19 19 19 19 19 19 13 15.5 
sigH 11 19 19 19 5 12 19 19 19 19 19 19 19 17.25 
fadD9 12 19 19 19 19 10 19 19 3 19 19 19 12 16.33 
gabD2 13 19 19 19 19 7 19 19 19 19 19 19 8 17.08 
Rv1421 14 19 19 10 6 19 19 19 19 19 19 19 7 16.17 
Rv1910c 15 19 19 19 10 19 19 4 19 19 19 19 19 17 
sigI 16 19 19 19 4 19 19 19 19 19 19 19 2 16.33 
menA 17 19 4 8 19 6 19 19 19 19 19 19 10 15 
fadE34 18 19 19 19 19 19 19 19 19 19 19 19 19 19 
recF 19 19 19 19 19 13 19 6 19 19 19 19 14 17 
 
Since the copy number data were exponential (base 2), it was necessary to transform them 
to obtain a robust estimate of the relationship between copy number in the treatment failure 
(sputum and BAL culture positive) and in the cures.  The RNA copy number data were 
ranked in descending order (most frequent RNA species set to 1) within each individual 
where 0 copies (undetected) was replaced by the highest rank (Table 22).  Rank order in this 
sense can be considered equivalent to quantiles.  The data were analysed in two ways: 1) 
Loess regression of all data points (ranks of cured being dependent variables and ranks of 
the treatment failure the independent variable), and 2) linear regression of the mean of the 
ranks of cured on the ranks of the treatment failure.  
 
The Loess regression showed that there is a correlation and that although non-linear (Figure 
15), it can be reasonably approximated by a line. Linear regression has the advantage that is 
more readily interpreted and provides a measure of the strength of the correlation (Figure 
16). The Loess estimate corresponds to a locally weighted mean, and we used the mean of 
ranks for the linear regression.  The fit was analysed for diagnostics of fit (QQ-plot and 
influence plot; data not shown).  The diagnostics suggested a good fit with a few genes 
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having sizeable residuals (hspX, sodA, and Rv3675), but still fell close to the expected QQ 
line; and some genes being influential (hspX, sodA, and rpsJ), although only sodA had a 
Cook’s distance barely more than 0.5 at high leverage (> 0.15). 
 
We estimated the correlation using the Pearson and Spearman methods, as well as using 
the result of ordinary least squares regression.  The Pearson correlation was 0.754 and the 
Spearman correlation was 0.774.  The regression estimate (slope) was 0.5664 (SE 0.1198) 
and the p-value of the regression fit was 0.0001947 (F-statistic: 22.35 on 1 and 17 DF).  
 
 
Figure 15 Loess regression of gene expression rank of cured patients on the rank of the failed patient. 
Since the data are integers several observations can occur with the same coordinates; the size of the 
dots is proportional to the number of coincident observations.  The Loess fit suggests a somewhat 
linear relationship, i.e., a correlation; the 95% confidence interval is shown in light blue shading. 
 




Figure 16 Ordinary least squares linear regression of mean rank of genes of cured on rank of failed 
case. 
The fit and 95% confidence interval (light blue shading) are shown. The fit is a reasonable 
approximation of the Loess regression fit. 
 The genes with the highest expression in the failed treatment samples were also the most 
abundant mRNA’s in the cured patients.  We speculate that the most abundant mRNA’s per 
bacterium are most easily detected when cell counts are low. 
3.7.13  Summary of associations. 
Significant associations included: 1) Clinical outcome was correlation with M6 scan response 
pattern and M6 sputum Xpert status.  2) Clinical status (new PTB diagnosis, PTB after 
treatment, latent TB or no TB) correlated well with the presence of MTB mRNA in sputum 
and BAL fluid.  3)  Poor adherence was association with a failed treatment outcome and M6 
sputum Xpert positivity.   
Comparisons where no significant association was found included:  1)  Clinical outcome was 
not associated with smoking status or previous PTB episodes.  2)  Neither the PET/CT 
response pattern, nor the lesion grading was correlated with M6 sputum Xpert positivity or 
adherence.  3)  There was no association between Xpert positivity and mRNA detection in 
M6 sputum.  
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4. Discussion:  Persistent lesions and MTB mRNA detected after 
treatment 
Summary 
We found ongoing inflammation, as detected by PET/CT, in the majority and the presence of 
MTB mRNA and DNA in respiratory samples from a substantial number of cured South 
African PTB patients at the end of treatment.  Similar PET/CT response patterns were seen 
in a smaller South-Korean cohort, for whom RNA data were unavailable. 
Significance of lesion activity after treatment 
Our study confirms the persistence of TB lung lesions previously described on CT and 
CXR.21,22 We also frequently found residual symptoms or signs after treatment, similar to 
other reports on post-tuberculosis lung sequelae.24–29,104  In addition, although most lesions 
improved and scan response patterns showed an association with clinical outcomes, we 
found that the majority of patients still had lesions with an ongoing inflammatory response on 
PET and roughly a third of patients showed intensified or new lesions.  These dynamic 
patterns were found after anti-TB treatment and even a year later, regardless of drug 
sensitivity, sustained culture conversion or clinical cure.  A European study on 35 patients 
with pulmonary or extra-pulmonary TB reported persistent PET/CT lesions in 15 and 
progressive lesions in 4 patients after a mean treatment duration of 16.1 months,73 while a 
Japanese study reported resolution of all lesions in 8 patients with DS-PTB after 12 months 
of treatment.72  It’s not clear whether the favourable scan outcome in the Japanese cohort is 
related to extent of disease, treatment duration, lower infection pressure or better living 
standards and health. 
FDG uptake only reflects the increased metabolic activity associated with inflammation and 
does not necessarily imply active MTB infection.  After the successful treatment of other 
infective lung pathogens, however, radiological lesions typically resolve within 6 weeks105 
and relative intensity on PET has shown correlation with MTB bacterial load in animal 
lesions.61  PTB related pathology is the most concordant with our PET/CT findings, 
considering the underlying morphology of individual lesions and the absence of clinical 
findings supporting other diagnosis.  Persistent antigens, associated with dead MTB, might 
lead to increased FDG-avidity after treatment, but it is unlikely to cause very high intensity, 
intensified or new lesions.  PET/CT imaging provides insight into the local host response and 
further research is required to unravel the interaction with MTB. 
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The individual fate of TB lung lesions have been demonstrated fairly consistently in reports 
of animal models: in Cynomolgus Macaques,62,63,106 as well as in rabbits61 and to some 
extent in mice.66  The similarities found between the clinical cases in our study, the first 
report of such comprehensively investigated patients, and the respective animal models add 
significantly to the importance of our findings. Our data provide support for the use of these 
different animal models in evaluating TB radiological response.  The demonstration of similar 
responses in humans and the animal models suggest that these animal models can indeed 
be used to build scientific hypotheses to explain our findings. 
What makes our findings even more interesting when compared to the animal models are:   
i) The spontaneous progression and resolution in of individual lesions on PET/CT in 
animal models were mainly described prior to anti-TB treatment, not during or after anti-TB 
treatment.    
ii) The longest treatment period in these models was 12 weeks, vs 24 weeks and EOT 
+ 1y for our clinical cases.  
iii) No increase in intensity or size of individual lesions were shown in animals after 8-12 
weeks on standard 4 drug anti-TB treatment, only on monotherapy.59  On 4 drug therapy all 
lesions improved. 
iv)   CFU numbers in animal lesions did correlate to reduction in PET uptake intensity. 
v)  Considering results from another mice model experiment,34 that demonstrated MTB 
mRNA transcripts in culture negative lesions taken from mice after 14 weeks of dual anti-TB 
treatment, followed by bacteriological relapse after high-dose steroid treatment in 21 of 23 
mice that were followed up, it is reasonable to propose that culture even culture negative 
lesions may harbor viable bacteria. 
Significance of MTB DNA and mRNA detection after treatment 
Our results confirm the high Xpert positivity rate previously reported in culture-negative 
sputum samples and noted an even higher rate in bronchoscopy samples.31,32 In addition, 
we detected MTB mRNA in 35% of culture-negative sputum samples at M6 and in all BAL 
fluid samples taken from 15 PTB patients at EOT.  Alpha-crytallin (hspX), linked to long-term 
MTB persistence,107 was present in 20 (27%) of the M6 sputum samples and 14 (93%) of the 
EOT BAL samples, while absent in M6 sputum and BAL of all controls.  The detection of 
MTB mRNA in 2 separate types of respiratory samples suggests either ongoing 
transcription, based on the short half-life of mRNA,14,15 or persistence of stabilised mRNA as 
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seen in non-replicating MTB in vitro.36  Although persistent MTB DNA in intact, non-viable 
bacteria may explain Xpert positivity, the same is unlikely to apply to MTB mRNA.  
Strengths and limitations 
This is the largest study examining PET/CT scans and mRNA TB patients at the end of 
treatment; however, it is a relatively small study, with a small number of unfavourable 
outcomes and without differentiation between relapse and re-infection.  We performed 
spoligotyping on sputum culture at diagnosis for most cases, but sputum culture was not 
available at time of re-diagnosis in most recurrent cases.  Other studies in Cape Town 
reported similar recurrence rates and if onset of recurrence occurred within 2 years of EOT, 
found roughly 66% due to relapse.9,10 We could not establish whether the positivity of some 
mRNA transcripts in the sputum of two controls could be the result of latent or subclinical 
MTB infection or transient MTB excretion after recent exposure;108,109 or eliminate the 
possibility that even pre-validated probes could show cross-reactivity.  However, in a blinded 
test, the EOT patients scored more MTB transcriptional signals, more frequently than the 
community controls and most probes did not show any positivity in the controls.  The extent 
to which the stochastic detection of low levels of MTB mRNA in individuals in communities 
with a high TB-burden represents true detection of MTB in individuals without manifestations 
of clinical TB has yet to be determined.   
The paradox that some samples were Xpert negative, but mRNA positive could be explained 
by the different sensitivities of the assays: the mRNA isolation procedures concentrate 
specimens prior to the assays and usually there are many copies of an mRNA species per 
genome copy.  We also observed Xpert-positive, mRNA -specimens, possibly due to greater 
stability of DNA.  In BAL samples, however, we observed a good concordance between 
mRNA and DNA detection, since the BAL samples were from targeted sampling of the 
affected lobe, processed immediately and concentrated.  The presence of DNA and mRNA 
in all BAL samples, suggest that both are usually present in parenchyma, but may be 
variable in sputum.  We found an excellent correlation between MTB mRNA in BAL and 
clinical TB status (p < 0.001; as noted in statistical associations section 5.7.4).  
Conclusion 
Our study was exploratory and the patients were investigated intensively, allowing 
complementary results from different tests.  In summary, we describe a marked 
heterogeneity in treatment responses of individual PET/CT lesions and the presence of MTB 
mRNA in sputum and BAL of a substantial number of cured patients at end of treatment. 
Although MTB mRNA stability remains a possible explanation for its presence in intact 
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bacteria, we suggest that viable MTB, with the potential to elicit a host response, often 
persists even after clinically curative treatment. The higher relapse rates in patient groups 
with impaired immunity8,17,43,110 support the concept that a competent immune response  
plays an important complementary role in the ultimate control of remaining bacteria after 
antibiotic treatment. The nature of host-pathogen interaction and association with poor 
treatment outcome and post-tuberculosis lung impairment need to be investigated in future 
studies.  Sterilising drug or host-directed therapies and improved treatment response 
markers are likely needed for the successful development of improved or shortened PTB 
treatment strategies.  
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5. Results: Operator independent technique to quantify widespread 
complex tuberculous lung lesions on PET/CT. 
5.1 Application of quantification technique 
As a proof of concept, the quantification methodology described in Section 2.6, page 19, was 
tested to quantify disease burden on PET/CT scans from five controls, and the first 5 
patients participating in the South-African PTB cohort.  The controls were from the same 
communities and had contact with PTB patients, but were sputum culture negative for 
mycobacterium tuberculosis and had no active lesions visible on PET/CT scan.  PTB cases 
were all diagnosed with drug-sensitive TB strains and were HIV uninfected.  Patients 
underwent scans at time-points within 1 week from initiation of treatment (Dx), after 1 month 
of treatment (M1) and after 6 months of treatment (M6), the duration of standard treatment.  
At the end of treatment, four of the PTB patients were classified as cured by healthcare 
providers in charge of treatment, while one was still sputum culture positive and diagnosed 
with a failed treatment outcome.   
Time requirements 
The quantification methodology was successfully implemented in all controls and patients.  
Creating the masks required a working knowledge of lung anatomy, while the other steps 
required basic computer literacy and a mid-range personal computer.  User input required 
for quantification could be divided into 1) file management, including the selection, indexing 
and formatting of image files; 2) creating VOI’s for lung masks, background references, as 
well as mediastinum and liver; 3) computation time, which included running the co-
registration algorithm and the quantification calculations.   
Time required to quantify the scans ranged from roughly 10 minutes for a single lesion-free 
lung scan (roughly 4 minutes for file management, 2 minutes computation and 4 minutes 
creating masks) to 45 minutes for a 3 time-points series of extensively diseased lungs 
(roughly 8 minutes file management, 12 minutes computation and 25 minutes creating 
masks).  Where applicable, cavity volume were easily measured with 3D MRICro region 
grow tool on CT, taking less than 1 minute per scan. 
Segmentation accuracy 
The auto-segmented MLV for each scan corresponded well to visual assessment of the PET 
scans. No false positive segmentation was noted on control scans.  In the PTB lung scans, 
all auto-segmented MLV’s corresponded to areas that appeared FDG avid.  False positive 
segmentation of uptake attributable to the liver or heart was noted in one case, which 
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necessitated repeating the quantification after adjusting the lung mask.  No visually FDG-
avid lesions were missed by auto-segmentation. Figure 17 compares the results from control 
cases with baseline PTB scans.  TGAI, MLV, Vhard and MLVabn, values approached zero for 
all controls, while showing increased values for all PTB scans.  The same, however, did not 
apply to Vsoft, which showed no clear distinction between the groups.  Vmedium values were 
below 2% for all controls and above 2% for all PTB patients.  A control case with markedly 
higher values for Vsoft and Vmedium, showed signs of chronic obstructive airways disease, 
which was the likely cause for abnormal lung densities.   
 




Figure 17 Comparison of PET/CT parameters between scans from 5 controls and 5 PTB patients at 
diagnosis. 
a)  Total Glycolytic Activity Index b)  Metabolic lesion volume. c) Vsoft (-500 HU:-300 HU) CT lesion 
volume as a percentage of total lung volume.  D)  Vmedium (-300 HU:-100 HU) CT lesion volume as 
a percentage of total lung volume.  E)  Vhard (>-100 HU) CT lesion volume as a percentage of total 
lung volume. E) Area of lung that shows abnormal density (>-500 HU) and relative high uptake 
intensity as a percentage of total lung volume. 
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Pilot case profiles 
Figure 18 demonstrates the dynamics of different scan parameters during treatment of the 
five PTB cases.  The segmented TGAI (Figure 18a) of 3 out of 4 cured cases already show a 
partial improvement (30%-62%) at M1 and continue to improve markedly towards the end of 
treatment.  The fourth cured patient shows a slight increase by M1, but improves significantly 
by M6.  After 6 months of treatment all the cured patients showed marked improvement (80-
99%), although only one patients showed nearly complete metabolic resolution.  The patient 
that failed treatment remained stable over the first month, but deteriorated by M6.  The MLV 
(Figure 18b) followed a very similar pattern during treatment. 
The total lung volume with increased density (Vsoft, medium, hard) followed a similar trend, 
although the reduction from Dx to M6 was less marked (41%-83%) and the failed treatment 
patient slightly decreased.  In the breakdown of different density lesions (Figure 18c-e), all 
cured patients showed a marked volume decrease in hard lesions, already noted by M1 
(35%-71%) and continued toward M6 (81%-98%).  The volumes of medium and soft lesions 
were more variable and a relatively large residual volume at M6.  Contributing factors to this 
might be conversion of voxels from Vhard to Vmedium and Vsoft during response to treatment, 
remaining post-TB fibrosis and a lower specificity at lower densities to pathological lesions. 
After 1 month of treatment, in cured patients’, MLVabN (Figure 18f) decreased modestly in two 
and remained stable in the other two.  The failed treatment patient showed a 13% increase.  
At M6, however, all cured patients showed marked decrease (82%-98%), while the failed 
treatment patient showed further increase. 




Figure 18 case-profiles of 5 PTB patients showing auto-segmented PET/CT parameters at Dx, M1 
and M6. 
Patient number 3 was the only patient with a failed treatment outcome (darker line).  A)  Total 
Glycolytic Activity Index B) Metabolic lesion volume .  C) Vsoft (-500 HU:-300 HU) CT lesion volume as 
a percentage of total lung volume.  D)  Vmedium (-300 HU:-100 HU) CT lesion volume as a percentage 
of total lung volume.  E)  Vhard (>-100 HU) CT lesion volume as a percentage of total lung volume. E) 
Area of lung that shows abnormal density (>-500 HU) and relative high uptake intensity as a 
percentage of total lung volume.   
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5.2 Quantified scan results from diagnosis, month 1 and month 6. 
Quantification was successfully performed on Dx, M1 and M6 scans from all 99 included 
participants in the South African cohort.  Two additional challenges were encountered during 
application of the technique that was not apparent during the pilot or control cases.  Firstly, 
Dx scans from two patients had such extensive disease, that it was impossible to identify 
visually lesion free areas of sufficient size to create two background references volumes.  To 
solve this we created four smaller NL volumes to serve as background reference.  Secondly, 
two other scans appeared to have some technical issues with the Dx scan that made the co-
registration algorithm ineffective.  This was resolved by co-registering Dx and M6 to the M1 
scan.  As previously discussed, cavity volume was measured separately in MRICro, using 
the 3D gradient based boundary tool. 
In this section we discuss the various quantified characteristics which were analysed in 
different ways.  The first analysis shows the relationship between changes in PET/CT 
metrics and time to sputum culture negativity.  Subsequently, we analyse the correlation 
between different scan parameters.  Finally, we discuss the risk of unfavourable outcomes 
entailed by different quantified PET/CT characteristics. 
PET/CT characteristics in relation to time to culture negativity group. 
Eighteen patients converted to sputum culture negative within 4 weeks, 39 by week 8, 22 by 
week 12, 9 by week 24 and 8 patients were still sputum culture positive after 24 weeks on 
treatment.  Three patients were excluded from this classification after a panel of experts 
concluded that contaminated culture results prevented accurate assignment of a TTN.  The 
mean value of all quantified scan parameters at each time-point were expressed in absolute 
values and proportional change from baseline.   




Figure 19 Mean (±SE) Log10 transformed values of principal PET and CT parameters over time by 
time to negativity group and recurrent cases. 
Total glycolytic activity index in a) absolute values and b) change from baseline.  Cavity volume in c) 
millilitres and d) change from baseline.  Total high density CT lesions in e) percentage of lung volume 
and f) change from baseline. 
TGAI, cavity volume and Vtotal could be considered the principal candidates to look for a 
measure to predict central trends for resolution or progression of lung pathology, since they 
hold the combined information from the main components:  volume and uptake intensity on 
PET scan, total high-density volume on CT and total cavity volume on CT.  A trend was 
evident for all three parameters, that and lower lesion burden was associated with earlier 
culture conversion and a higher burden with later conversion (Figure 19).  This feature was 
most explicit for cavitation, where a significant difference between failed treatment cases and 
other groups were already seen at Dx.   
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Differentiation between the TTN groups tended to become more pronounced over time.  This 
was confirmed by the graphs showing the change from baseline.  It was less evident for 
cavity volume, where all TTN groups showed a rapid decline over the first month of 
treatment, but some stabilisation towards M6.  However, stability from M1 – M6 was also 
seen in the W4 culture conversion group (fastest responders), which was likely influenced by 
the smaller initial cavity volume, resulting in earlier resolution with less room for 
improvement.  
Unlike failed treatment cases, the recurrent patients did not have a large comparative 
baseline burden of disease.  The recurrence group however, did show comparatively less 
improvement over time and even deteriorated in terms of cavitation volume.  
  




Figure 20 Mean (±SE) Log10 transformed values of PET parameters over time by time to negativity 
group 
Maximum lesion intensity in a) SUVmax and b) change from baseline.  Mean lesion intensity (Zmean) in 
c) mean Z-score and d) change from baseline.  Metabolic lesion volume in a) percentage of total lung 
volume and b) change from baseline. 
Absolute values of maximum or mean lesion intensity did not show any prognostic or 
diagnostic potential.  When expressed in terms of proportional change over time, however, 
both correlated very well with TTN groups (Figure 20).  The SUVmax for the slow 
responders even showed a slight increase at M1.  Metabolic lesion volume performed very 
similar to TGAI, but did not seem to differentiate the TTN groups quite as well. 




Figure 21 Mean (±SE) Log10 transformed values of CT parameters at Dx, M1 and M6 by time to 
negativity group. 
Soft lesions (Vsoft) in a) percentage of total lung volume and b) change from baseline.  Medium lesions 
(Vmedium) in a) percentage of total lung volume and b) change from baseline.  Hard lesions in a) 
percentage of total lung volume and b) change from baseline. 
In all the subdivisions of high-density lesions, failed treatment cases had significantly greater 
volume compared to cured cases.  This was evident from as early as M1 and the gap 
between the groups became wider by M6 (Figure 21).  Vhard showed a rapid decrease in 
volume in all groups.  A rapid decrease by M1 is also noted for fast responders in Vmedium and 
Vsoft.  For failed treatment cases, the mean for Vmedium decreased only gradually and for Vsoft 
an increase was seen in the first month.   




Figure 22 Mean (±SE) Log10 transformed values of combination PET/CT parameters at Dx, M1 and 
M6 by time to negativity group. 
Volume with increased density and metabolic activity (MLVabn) in a) percentage of lung volume and b) 
change from baseline.  Weighted mean of cavity volume combined with MLVabn in c) total and d) 
change from baseline. 
Since MLVabn is a combination PET and CT parameters, we expected it to show improved 
diagnostic accuracy and a very high specificity for diagnostic.  While it did correlate to TTN 
groups (Figure 22), neither the absolute values nor the change from baseline seemed to 
perform better than the separated components.  When a weighted cavity volume was added, 
however, the graph seemed to better differentiate the fast responders (TTN ≤ 4weeks) and 
failed treatment cases across time-points.   
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Correlation between imaging parameters 
 
Figure 23  Correlations matrix of quantified scan parameters at Diagnosis. 
Corresponding scatterplots left and below variables and correlation coefficient right and above. 
 




Figure 24 Correlation matrix of quantified scan parameters at M1. 
Corresponding scatterplots left and below variables and correlation coefficient right and above. 
 




Figure 25  Correlation matrix of quantified scan parameters at M6.   
Corresponding scatterplots left and below variables and correlation coefficient right and above. 
We assembled correlation matrices of the principal scan parameters during treatment 
(Figure 23, Figure 24, Figure 25).  TGAI and MLV were strongly correlated at all time-points.  
This was in keeping with the similar performance in PET TTN group analysis.  Vtotal showed a 
moderate correlation with TGAI and slightly stronger correlation with MLV at Dx, but the 
relationships gets weaker towards M6. Cavity volume was the most independent variable at 
all time-points.  Combined parameters (MLVabn Weighted cavity volume/MLVabn) showed 
strong correlation with related components, as expected.  
Lung cavities on PET/CT has distinct characteristics when compared to other PET/CT 
parameters.  While they form part of a pathological process and therefor represent diseased 
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lung, the lack of perfusion renders it devoid of FDG uptake.  Thus, the potential for improved 
specificity by the addition of the PET component is lost.  This also is responsible for the 
independence from other scan parameters.  We tried to optimise the accuracy of cavity 
volume as measure of disease burden, by assigning the Zmean from the rest of the lung to the 
cavity volume.  The theory behind this was that if a low inflammatory response existed in the 
cavity wall and other lesions around the cavity, then the cavity is more likely to be inactive.  
Cavities serving as a reservoir of active MTB, on the other hand, would likely influence the 
surrounding tissue and lesions, in a pro-inflammatory manner.  The resulting formula was: 
Cavity volume (ml) x Zmean = Total glycolytic activity index in cavity volume (TGAIcav).  
TGAIcav could also then be added to TGAI, to create a combined PET/CT parameter 
(TGAIcom) that include information from almost all PET/CT parameters without the need for 
more complex statistical conversions. 
 
Figure 26  Correlation between values of imaging parameters and TTN 
 




Figure 27  Correlation between imaging parameters’ change from baseline and TTN 
In Figure 26 and Figure 27 we compare the correlations between the various imaging 
parameters and TTN groups.  Absolute values of cavity related parameters performed the 
most consistently across time-points – Cavity volume slightly better early in treatment and 
TGAIcav slightly better at M6.  TGAI performed the most consistent across time-points in 
terms of change from baseline and TGAIcom performed strongly in both analyses. 
Prognostic factors of failure 
As expected from TTN correlation results, Cavity volume was the best predictor of treatment 
failure.   




Figure 28  Example of PET/CT scan of failed treatment case at Dx, M1 and M6. 
Large, bilateral upper lobe cavities with thick, dense walls with intense FDG-uptake can be seen 
throughout treatment. 




Figure 29 Receiver operating characteristic (ROC) curves of cavity volume predicting failed treatment. 
Apart from cavity volume, other parameters reflecting the volumetric lesion extent also 
performed fairly well at predicting failure at Dx, while parameters reflecting glycolytic activity 
performed stronger at M6 (Figure 27).  
In addition to cavity volume, M6 cavity wall thickness also correlated to failure.  For each M6 
scan, we measured the wall of the cavity that appeared the thickest, at the level of the 
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maximum transverse cavity diameter.  In most cured cases, M6 cavity volume ranged from 
zero (no cavity), to 3mm.  Month 6 cavity wall thickness in failed cased were significantly 
different (Student’s T-test for independent samples; P < 0.001) and ranged from 2.5mm  to 
7mm.  Recurrent cases were not significantly different and M6 cavity wall thickness ranged 
from zero to 4mm.  The distribution for the groups is shown in Figure 30.   
Measurement of cavity walls required a degree of interpretation due to irregular borders, 
confluence with other lesions and structures, as well as fibrotic changes (examples shown in 
Figure 31).  Therefor it likely to be subject to inter-reader variability. 
 
Figure 30  Box and whisker plot of M6 cavity wall thickness, showing the median, 25th & 75th 
percentile (Box) and range (whiskers). 
 




Figure 31  Examples of cavity lesions on M6 CT images. 
a) A failed treatment cases with a well-circumscribed cavity with a 6 mm wall.  b)  Cavity with a 1.5mm 
wall on the CT images of a cured patient.  c)  A cured patient with cavity and confluent nodule.  d) A 
cured patient with extensive right upper lobe fibrotic changes and destruction. 
Prognostic factors of recurrence 
The twelve patients diagnosed with recurrent disease within 2 years after treatment did not 
show a comparatively large lesion burden at Dx (Figure 19), but did show a relative slow rate 
of improvement.  The mean TGAI for the recurrent group improved at a similar rate to 
patients with a TTN of 24 weeks from Dx to M1 and M6, even though the median TTN for 
recurrent cases were 8 weeks (  




A similar trend was seen for Vtotal and Zmean, but was less apparent.  Mean cavity volume 
decreased over the first month of treatment, but deteriorated between M1 and M6.  
At M1, there was a trend for the recurrent group to have a smaller reduction in TGAI and 
TGAIcom burden.  At M6, the difference between the groups were significant (Figure 32 & 
Figure 33).  No other parameters were significantly different between cured and recurrent 
groups. 
 
Figure 32  Mean ± SE ± 1.96xSE Change in TGAI for cured and recurrent groups 
a) From Dx to M1 (p = 0.3)       b) from Dx to M6 (p = 0.003). 




Figure 33 Mean ± SE ± 1.96 x SE Change in TGAIcom for cured and recurrent groups 
a) From Dx to M1 (p = 0.3) and b) from Dx to M6 (p = 0.02). 
Criteria for unfavourable outcomes 
We then pooled patients with unfavourable outcomes (failed and recurrent treatment) and 
performed further analysis to find the best criteria to predict recurrent disease.  We analysed 
the most promising scan parameters’ distribution per cured and recurrent groups, combined 
with ROC curve analysis to determine the most informed thresholds. 
Table 23  Summary of Contingency table statistics for scan parameters. 
Ranked according to relative risk of unfavourable outcome.  Fisher exact test was performed to 
determine significance. PPV (positive predictive value), NPV (Negative predictive value), Change 
(change from baseline), intensified (at least one intensified or new lesion). 
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No. that met criteria (n = 
96) 
Parameter P - value 
Relative 
risk Sensitivity Specificity PPV NPV Criteria Cured Fail Recur 
TGAI Change 
M6 <0.0001 6.97 0.80 0.75 0.46 0.94 < 80% 
19 7 9 
TGAIcom 
Change M6 <0.0001 6.67 0.80 0.74 0.44 0.93 < 80% 
20 7 9 
Cavity M6 <0.001 4.36 0.55 0.86 0.52 0.88 > 7mm3 
10 7 4 
Cav Change 
M6 <0.01 4.30 0.65 0.79 0.45 0.90 < 60% 
16 6 7 
TGAIcom3 <0.001 4.05 0.50 0.88 0.52 0.87 > 1000 
9 6 4 
TGAI M6 <0.001 4.05 0.50 0.88 0.53 0.87 > 600 
9 6 4 
Mixed 
response M6 0.02 2.86 0.60 0.72 0.36 0.87 
Intensifi
ed 
21 8 4 
Cav Change 
M1 0.01 2.80 0.50 0.80 0.40 0.86 < 33% 
15 5 5 
Cavity M1 0.04 
2.50 
0.35 0.87 0.41 0.84 >20mm3 
10 6 1 
TGAI Change 
M1 0.07 2.24 0.40 0.82 0.36 0.84 <5% 
14 4 4 
TGAIcom 
Change M1 0.16 1.80 0.40 0.76 0.31 0.83 15% 
18 3 5 
Cavity Dx 0.18 1.72 0.45 0.72 0.29 0.83 
> 
16.5mm3 22 6 3 
 
Less than 80% reduction in total glycolytic activity from Dx to M6 was the best predictor of 
unfavourable outcomes with an almost 7-fold risk if these criteria was met.  Adding the 
assigned cavity activity (TGAIcav) to generate TGAIcom, did not improve accuracy, despite 
cavity volume improvement of less than 60% from baseline also performing well as an 
independent predictor of unfavourable outcomes.  
A total M6 Cavity volume greater than 7mm3  and a M6 TGAI of greater than 1000 also 
carried an increased risk to have an unfavourable outcome of more than 4 times.  Cavity 
volume was slightly more sensitive and TGAI more specific.  Combining the variables did not 
improve accuracy.  TGAIcom performed identical to TGAI.  We also applied criteria in which 
either M6 cavity volume > 7mm3, or TGAI > 1000 put a patient in the high-risk group, but this 
generated the same sensitivity and lower specificity. 
All these M6 quantified parameters performed better than the lesion based qualitative 
measure.  A mixed response pattern at M6 was associated with a 2.86 times increased risk, 
which was comparable to the best quantified parameters at M1.  
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At month 1, both a cavity volume greater than 20mm3 and a lack of at least 33% cavity 
volume reduction from Dx were significantly associated with a poor outcome – showing a 2.5 
and 2.8 times increased risk of unfavourable outcome respectively.  A trend was found for 
high cavity volume at Dx to be associated with unfavourable outcomes – largely driven by a 
strong association to failed treatment cases. 
A trend was found that less than 5% reduction of TGAI at from Dx to M1 was associated with 
an unfavourable outcome.  Due to recurrent cases presenting with a lower mean TGAI 
burden at Dx than cured patients, total TGAI values at Dx and M1 did not perform well as a 
predictor of pooled unfavourable outcomes.  
5.3 Quantified scan results: EOT + 1y. 
Residual lesions 
As discussed in section 3.4 (page 38) 50 patients were scanned again 1 year after the end 
of treatment.  Forty-two of these patients maintained cure, while eight were diagnosed with 
recurrent disease (Figure 11).  At EOT + 1y, only 32% of EOT + 1y scans were completely 
resolved.  Significant residual lesion(s) were found in 68%, of which half had improvement of 
all lesions and the other 34% a mixed lesion response compared to the M6 scan (Page 38).  
However, there was improvement in size and intensity of most residual lesions when 
compared M6.   
When compared to Dx, only nine cases (five of which were recurrences) showed less than 
80% improvement of TGAI by EOT + 1 and only three cases (2 of which recurrences) had 
more than 7mm3 total cavity volume.  The distribution of TGAI and cavity volume across 
time-points are shown in Figure 34 and Figure 35. 




Figure 34  Box and whisker plot showing median, quartiles and range for TGAI at Dx, M6 and EOT + 
1y. 
Grouped in Cured and recurrent patients.  Y-axis truncated. 




Figure 35  Box and whisker plot for Cavity volume at Dx, M6 and EOT + 1y. 
Grouped in Cured and recurrent patients, showing median, quartiles and range.  Y-axis truncated. 
MLV decreased to a median of 0.69% of lung volume at EOT + 1y.  Vtotal showed more 
residual lesion volume, with a median of 3.58% of total lung volume at EOT + 1y. 




Figure 36 Box and whisker plot for MLV and Vtotal at Dx, M6 and EOT + 1y. 
Showing median, quartiles and range. 
For recurrent cases, the range of glycolytic activity and cavity volume, were not as high at 
EOT + 1y as we found at original diagnosis.  Two factors would likely influence these 
findings.  Firstly, three of the patients already received partial re-treatment.  Secondly, the 
fact that the patients were actively followed up, may have decreased the time from 
reactivation or reinfection until diagnosis. 
Correlations between M6 and EOT + 1 year findings. 
There were no significant association between a mixed response at M6 and a mixed 
response at EOT + 1 year (Table 24).  Figure 37 and Figure 10 shows examples of dynamic 
lesion progression and resolution during and after treatment. 
Table 24 Association between mixed scan response patterns at M6 and EOT + 1y. 
Fisher exact test p = 0.18. 
  M6 Mixed M6 Resolved/Improved Totals 
EOT + 1y Mixed  7 10 17 
EOT + 1y Resolved/Improved  8 25 33 
Totals 15 35 50 




Figure 37  Dx, M1, M6 and EOT + 1y PET/CTs for 3 representative cases.   
3-dimensional anterior and transverse slices at the level of horizontal blue line.  a) Residual cavitation 
with moderate FDG-avidity at M6, improves over the next year, leaving nodular infiltrate with mild 
activity. b) New nodule with high intensity seen at M6 resolves, but 2 new nodules are seen at EOT + 
1y.  c) All lesions resolved at M6, but 3 new areas with small nodular and tree-in-bud infiltrates seen. 
All 3 patients received 6 months of standard treatment and maintained cure. 




Figure 38  Scatterplots to show correlation of PET/CT scan parameters at M6 and EOT + 1y. 
a) TGAI, weak positive correlation, non-significant.  b) Cavitation volume, no significant correlation. c) 
Vtotal, significant positive correlation.  d) SUVmax, moderate, but significant positive correlation. 
No significant association was found between M6 and EOT + 1y for TGAI or cavity volume 
[Figure 38 a) & b)].  However, we found a moderate correlation between the time-points for 
Vtotal and SUVmax.   
Differences between recurrence and maintained cure. 
Applying two-tailed Student’s T-tests for independent samples, we found significant 
differences at EOT + 1y between cured and recurrent patients for TGAI (P < 0.01), Cavity 
volume (P < 0.01), MLV (P = 0.01) and SUVmax (p = 0.04), but not for Zmean, Vtotal or CT 
density subgroups (Vsoft, Vmedium, Vhard).    
Since there was no consistent spacing between the timing of the scan and re-treatment 
initiation, analysis to define an EOT + 1y criteria to differentiate maintained cure from 
recurrence was not deemed appropriate. 
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5.4 Statistical associations with quantified PET/CT parameters. 
Association with Microbiological markers 
We performed student’s T-tests, with analysis of variance and homogeneity to test for 
significant associations between Xpert positivity at M6 and scan parameters. 





















TGAI M6 278.41 964.56 < 0.001 < 0.001 < 0.001 68 30 
TGAI Change 
(Dx-M6) 
0.84 0.69 0.001 0.001 < 0.001 68 30 
Vtotal3 1.70 2.72 0.039 0.011 0.04 68 30 
Cavity3 10.31 11.85 0.846 0.515 0.001 68 30 
Cav Change (Dx-
M6) 
0.60 0.60 0.969 0.082 0.01 68 30 
TGAIcom M6 434.87 1190.12 0.003 0.004 < 0.001 68 30 
TGAIcom Change 
(Dx-M6) 
0.82 0.69 0.004 0.033 0.002 68 30 
 
 
Figure 39  Association between M6 Xpert positivity, M6 TGAI and TGAI change from Dx. 
Box and whisker plot showing Mean, ±SE, ±1.96×SE. 
At M6 we found the clearest difference between Xpert negative and positive groups for M6 
TGAI and proportional change in TGAI from Dx to M6.  TGAIcom and Vtotal also showed 
significant differences.  Xpert positivity at M6 was associated with less improvement during 
treatment and a higher lesion burden at the end of treatment.  We also found a linear 
correlation between Xpert Cycle threshold values at M6 and M6 TGAI (r = -0.43; p < 0.0001) 
and TGAI change from baseline (r = 0.43, p < 0.0001).  Using the non-parametric Mann-
Whitney U-test (likely more accurate due to the positive skew in cavity volume distribution), 
we also found a significant difference for cavity volume or cavity change from Dx–M6.   
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We performed the same analysis to test for an association between the main scan 
parameters and m6 sputum MTB mRNA positivity and found no significant associations.  We 
also found no linear correlation between the number of positive MTB transcript targets and 
the quantified scan values.    
 
Figure 40  Correlation between the number of MTB mRNA transcripts detected in EOT BAL and M6 
cavity volume. 
We found a linear correlation between cavitation volume and the number of positive MTB 
transcript detected in EOT bronchoalveolar lavage fluid (Figure 40), but no other scan 
parameters.  
At Dx, we found a non-significant negative correlation between days to liquid culture 
positivity (TTP) and cavity volume (r = -0.2 p = 0.05), and a significant negative correlation 
with TGAI (r = -0.27, p = 0.008), which was slightly strengthened by adding the influence of 
cavitation to create TGAIcom (Figure 41) 




Figure 41  Scatterplot of correlation between TTP and TGAIcom. 
To look for different response in different strains, we collapsed the strain clades into those 
with the Beijing strain and other strains and performed two-tailed, T-tests for independent 
samples. The Beijing strain was grouped since this strain was the most prevalent in our 
cohort and have previously been linked to an increased risk for treatment failure.41,42   


















TGAI Dx 2409.53 2856.10 0.32 0.01 0.82 51 38 
TGAI M6 513.42 537.09 0.90 0.19 0.04 51 38 
TGAI Change 
(Dx– M1) 
0.24 0.28 0.64 0.67 0.03 51 38 
TGAI Change 
(Dx–M6) 
0.77 0.82 0.32 0.62 0.03 51 38 
Cavity1 18.84 23.11 0.55 0.44 0.87 51 38 
Cavity3 14.33 7.97 0.43 0.23 0.05 51 38 
Cav Change 
(Dx–M1) 
0.38 0.68 0.0004 0.0005 0.001 51 38 
Cav Change 
(Dx–M6) 
0.48 0.82 0.02 0.001 0.01 51 38 
Vtotal1 5.53 5.85 0.63 0.03 0.99 51 38 
Vtotal3 1.93 2.35 0.42 0.04 0.73 51 38 
Vtotal Change 
(Dx–M6) 
0.66 0.64 0.68 0.01 0.48 51 38 
 




Figure 42  Association between grouped strain clades and change in cavity volume from Dx to 
M1&M6. 
Box and whisker plot showing median, quartiles and range . 
We found no difference between the groups at Dx.  The group infected with Beijing strains, 
however, did have a significantly less improvement in proportional cavity volume from 
baseline to M1 and M6 (Table 26; Figure 42).  This resulted in a trend for higher cavity 
volume at M6 in the Beijing group. 
Association with clinical factors 
We performed student’s T-tests, with analysis of variance and homogeneity to test for 
significant associations between a history of previous PTB episode(s) and scan parameters. 





















TGAI Dx 2279.98 3054.43 0.083 0.033 0.83 68 31 
TGAI M6 302.07 891.25 0.001 <0.001 0.047 68 31 
TGAI Change 
(Dx–M6) 
0.84 0.70 0.003 0.003 0.029 68 31 
Cavity1 18.04 22.41 0.526 0.798 0.87 68 31 
Cavity3 11.01 9.96 0.893 0.479 0.057 68 31 
Cav Change (Dx–
M6) 
0.65 0.45 0.211 0.209 0.01 64 31 
TGAIcom (Dx–
M6) 
472.43 1079.44 0.016 0.005 0.058 68 31 
TGAIcom Change 
(Dx–M6) 
0.82 0.71 0.025 0.058 0.02 68 31 
Vtotal Dx 5.41 5.95 0.428 0.413 0.99 68 31 
Vtotal M6 1.83 2.38 0.266 0.725 0.48 68 31 
 




Figure 43 Association with between a history of previous PTB episode(s) and TGAI at Dx and M6. 
Box and whisker plot showing Mean, ±SE, ±1.96×SE. 
There was a trend for patients with previous PTB to have a higher TGAI burden at Dx and a 
significant association between higher TGAI at M6 and less improvement from Dx to M6 and 
previous PTB episodes.  We found no significant difference for cavity volume or CT density 
areas.  Using non-parametric testing (Mann-Whitney U-test), however, we found significantly 
less reduction in cavity volume in patients with previous PTB.   
We tested for a significant association between documented treatment dosages missed 
during follow-up and M6 scan parameters, by doing Student’s T-Tests, checking for linear 
correlations and found no significant association.  We also performed a Fisher Exact on the 
cross-tabulation of patients that missed more than 80% of treatment and those with less than 
80% TGAI reduction from Dx to M6 and found no significant association. 
We also did not find a significant difference between quantified PET/CT parameters and a 
history of smoking or the PTB symptom score.  
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6. Discussion: Operator independent technique to quantify 
widespread complex tuberculous lung lesions on PET/CT.   
6.1 The use of the quantification technique 
Summary 
We devised a quantification technique to reproducably quantify pulmonary tuberculosis 
lesions on PET and CT.  This method is described in section 2.6, page 19 and details of the 
application provided in section 5.1, page 59.  We used patient specific reference volumes to 
reduce intra- and interscan variability on PET and auto-delineation to reduce inter-reader 
and inter-operator variability when assessing multiple widely distributed lesions with complex 
morphology.  The technique quantifies lesions throughout the lungs to measure the central 
trend of disease progression or resolution, thus accounting for the variable response of 
individual lesions during PTB treatment response.  
Optimal adaptive thresholds for auto-segmentation of PET scans were determined by using 
a small number of control lung scans and scans containing lesions with minimal to mildly 
increased uptake.  Density thresholds for CT scans were determined using values previously 
reported in literature.  We tested the technique in a pilot set of control cases and in PTB 
cases during treatment.  The  quantified variables correlated well with manual visual scan 
interpretation and clinical outcomes.   
Novel aspects of quantification technique 
The technique introduced some novel concepts in PET/CT analysis, including the use of a 
patient specific reference volume to standardardise the lung uptake; whole lung automated 
segmentation of CT lesions; and bivariate quantification of PET and CT images.  It also re-
applied concepts previously used in other settings, such as co-registration of corresponding 
scans at different time-points, whole organ automated segmentation of PET uptake and 
joint-segmentation of PET and CT.86   
Strengths and limitations of technique 
Some challenges and potential drawbacks were encountered during the application. 
Using the 3D region grow tool in MRICro was user friendly and easily reproducable, 
however, some manual imput was required when drawing the lung mask, to include dense 
lesions extending into the chest wall, and areas affected by misregistration.  This may be 
more time-consuming and could lead to some inter-user variability, however it should lower 
than manual delineation of each individual lesion.  Although the segmented volumes were 
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visually compared to the source scans, we were not able to compare directly to an objective 
ground truth, due to lack of available histology or gold standard segmentation techniques for 
complex lesions. Testing the technique using a phantom scan may be limited, since the 
results may not be accurate when derived from a scan with an artificially homogenous 
background.  Comparing to a ground truth in future analysis may however be useful, but 
given that the main goal of this technique is to reduce interscan variability in longitudinal 
follow-up and not planning surgical interventions or radiation therapy, this is likely to be less 
crucial. 
Co-registering baseline and follow-up scans allowed the user to generate a single lung mask 
and reference volume to use across all time points.  This should reduce interscan variability 
between follow-up scans and save time.  It did not, however, allow the measurement of 
change in total lung volume over time, which may occur during lesion resolution with 
associated fibrosis formation.  Re-slicing allows direct comparison of PET and CT 
components using a single VOI.  A disadvantage is that there is a smoothing effect on the 
CT images. 
Using the mean and standard deviation of 2 reference volumes to standardise lesion to 
background activity should notably decrease inter-scan and inter-patient variability compared 
to techniques that normalise the uptake to reference volumes from other organs or a 
theoretical whole body concentration.   
The technique was useful to report trends, but a possible drawback is that Z-scores are a 
statistical measure not routinely used in reporting, which may require additional conversions 
when applying research findings to a clinical setting.   
Auto-delineation of the whole lung allowed for the segmentation of multiple lesions with 
widespread distribution and variable intensity, size and morphology. This is expected to 
greatly reduce inter-reader variability, especially in a self-controlled study measuring 
changes after interventions.  The technique was not specific enough to delineate cavity 
volume, and an additional manual step was required to perform this function. 
Conclusion 
This technique to auto-segment and quantify multi-focal and complex lung lesions of PET 
and CT showed great promise in a pilot set of subjects, and required limited operator input. 
Further application to a larger number of subjects were of value to further validate the 
measures against clinical and research outcomes.  Ultimately this methodology, or some of 
the features, could easily be incorporated into standard clinical analysis programs and 
reporting protocols. 
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6.2 Quantified PET/CT results. 
Summary of main findings 
We successfully implemented the automated quantification technique on all PET/CT scans 
of patients included in the analysis. 
We found a good correlation between quantified PET/CT scan characteristics and micro-
biological measurements, such as time to culture negativity, days to liquid culture positivity at 
diagnosis and Xpert positivity at M6.  We also found a good correlation between the scan 
parameters and treatment outcomes, as well as a history of previous PTB episode(s).  While 
even most cured cases did not manage complete resolution of lesion burden, quantification 
resulted in much improved prognostic indicators of treatment outcome. 
A summary of suggested thresholds for most prominent scan parameters at different time-
points and the relative risk, sensitivity, specificity, negative predictive value and positive 
predictive value are shown in Table 23. 
To summarise findings relating to cavity volume:  1) Cavity volume had the strongest 
correlation with sputum culture positivity and TTN.  2)  It showed the best predictive ability at 
early time-points, with an AUC of > 80% at Dx, M1 and M6 to predict treatment failure.  A M6 
cavity volume greater than 7mm3, or a reduction less than 60% was associated with an 
unfavourable outcome. 3) Cavity volume was the only parameter that showed a significant 
correlation with mRNA detection in BAL fluid and a non-significant association with mRNA in 
sputum detection.  4)  A lack in cavity volume reduction from diagnosis was a significant risk 
factor for recurrent disease.  5) Infection with the Beijing strain was associated with a lack of 
reduction in cavity volume from Dx. 
To summarise findings related to total glycolytic activity index:  1) A suboptimal reduction in 
TGAI was the greatest risk factor for unfavourable outcomes.  At least 5% reduction in TGAI 
during the first month of treatment and at least 80% reduction by the end of treatment should 
be expected during a favourable response.  2)  The change in TGAI from Dx to M6 also had 
the strongest association with Xpert positivity at M6.  3) TGAI showed the strongest 
correlation to sputum culture TTP at Dx. 4) In patients with previous episodes of PTB, we 
found a suboptimal reduction in TGAI from baseline, which resulting in a higher TGAI load at 
M6. 
The volume of high-density lesions on CT (Vtotal) showed a relatively good correlation with 
TTN and failed treatment, even in early treatment, with Dx to M1 change in Vmedium showing 
good correlation.  Later in treatment, however, density changes were less dynamic when 
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compared to TGAI and a weaker association with recurrent disease and subsequently, 
pooled unfavourable outcomes were found.  
Values indicating FDG uptake intensity (SUVmax and Zmean), did not show any correlations 
early in treatment.  However the proportional intensity change over time did correlate to TTN 
and outcome, although not as strongly as TGAI, which combines intensity and volume. 
We also combined promising parameters from PET and CT in different ways:  using 
combined segmentation, statistically adding a weighted cavity volume, assigning an intensity 
value to cavity volume and creating a combined criteria of both TGAI and cavity volume 
thresholds.  While these combined parameters performed similar to their underlying 
components, we did not find them to be superior to these components. 
We did not observe any correlation between documented poor adherence and scan 
parameters or pooled unfavourable outcome and found this a noteworthy negative finding.  
As noted earlier (Table 1), the mean amount of treatment dosages missed were significantly 
increased for patients that failed treatment. 
Quantification of EOT + 1y scans confirmed our previous observations that there was a 
tendency for all parameters to reduce after treatment, but that a lack of complete resolution 
was still common and dynamic changes often seen.  Dynamic changes were common for 
PET parameters and resulted in a poor correlation between M6 and EOT + 1y 
measurements, compared to CT lesions which appeared more persistent after treatment.  
We did not find a trend for mixed response patterns at M6 to be associated with mixed 
patterns at EOT + 1y (note that failed treatment cases were not included in EOT + 1y 
analysis). 
As expected, recurrent disease was associated with significantly increased TGAI, Cavity 
volume, MLV and SUVmax, but not Zmean, or Vtotal. 
Comparison with previous literature. 
Our quantified findings correspond well with previous reports on animal models.  In rabbit 
and primate models, SUV intensity of individual lesions only loosely correlated with bacterial 
load prior to treatment, 61,62 while on treatment, both the change in lesion size and the 
change in intensity, independently showed a better correlation to bacterial lesion load and a 
negative correlation to the potency of the chemotherapy used.  In our study, lesion intensity 
did not correlate with microbiological markers or outcome, but the proportional change in 
intensity did.  Both the total lesion volume and the change volume correlated with outcome 
and microbiological markers.  On treatment, the main focus in these studies were correlation 
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of lesion specific scan parameters with the MTB bacterial load in the lesions at necropsy and 
did not comment on total lung burden and outcome, compared to our study, were histology 
was unavailable and longitudinal clinical outcome was the main independent variable.  
Before treatment, however, Via et a.l61 and Coleman et al.106 did find the central trends to 
correlate with progression to active disease and in a mouse model, a rise in mean PET 
activity (SUVmean) preceded culture positive relapse after initial treatment.66  Our findings 
also correspond with the rabbit model,61 that showed FDG uptake intensity change prior to 
lesion density changes. 
An important difference between animal models and human PTB must be noted: The time of 
initial infection in laboratory animals is always known and interventions would likely follow at 
a comparatively early stage and may lead to less complex or less established lesions, such 
as thick walled cavities. 
This is the largest study conducted on the use of 18F-FDG PET/CT in human patients with 
PTB.  The prospective follow up and in depth additional investigations and analysis, sets it 
apart from most other reports in literature on this subject, which often included small sample 
sizes, varying levels of follow-up and a lack of objective results for comparison.  Our 
quantification of scan parameters allowed the detailed description of scan changes over time 
and the comparison of these changes to objective microbiological and clinical outcomes.  It 
was also the first study to report on the fate of residual PET/CT lesions after PTB treatment. 
Our findings were in keeping with the two most comparable human studies in regards to 
study design and the depth of analysis (both conducted in drug resistant PTB cases).  
Coleman et al. found that adding Linezolid to a failing XDR treatment regimen significantly 
decreased the total glycolytic activity in lung lesions (segmented by using fixed thresholds) 
within 6 months of follow-up.  The sharpest decline in lesion burden was seen in the first 
month.  Chen et al. 75 addressed the prognostic ability of PET and CT changes, by showing 
a correlation between the change in total glycolytic activity after 2 months, as well as a  
change in CT reader scores in the lungs after 6 months and treatment outcome in MDR 
patients.   
Our results also confirm the previous reports that cavitatory disease is associated with a 
poor outcome.8,19,111 Unlike some previous reports, we did not find a correlation between 
month 2 culture conversion and pooled unfavourable outcomes.  We also found a no 
association between adherence and recurrent disease. 
We did not find an association between infection with the Beijing strain and failed 
treatment.41,42  The Beijing strain, however, was associated with a suboptimal reduction in 
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cavity volume during treatment.  This is an interesting finding and if this could be validated in 
future studies, might in part help to explain the strains rapid increase in incidence. 
The persistence of density changes in the lungs are also in keeping with reports of the high 
incidence of post-tuberculosis lung impairment.  
Study Limitations 
Limitation to the study design were discussed in chapter 4, page 57.  Limitation to the 
quantification techniques is discussed in section 6.1, page 93. 
An additional limitation in the design, not previously mentioned, was the in-availability of 
pharmacokinetic testing, due to insufficient resources. 
While the strong association found between our quantified results and microbiological and 
clinical variables would suggest that the segmentation and automated quantification 
technique is of value, the absence of a ground truth, we cannot exclude the possibility that 
other analysis methods could improve on the prognostic ability of scan characteristics.   
At month 6, the best predictor of unfavourable outcomes showed 80% sensitivity and 75% 
specificity, which is modest for a diagnostic test but far superior to currently used predictive 
biomarkers for poor treatment outcomes.  Including month 2 sputum culture conversion, 
sputum smear conversion at month 2 and month 5, as well as Chest X-rays and CT scans.  
Nevertheless, we noted that some patient outcomes were not predicted correctly, including 
some poor outcomes in patients with excellent improvement on PET/CT scans and some 
patients who maintained clinical cure in spite of a large and dynamic FDG-avid lesion load 
detected on PET/CT M6.  For this reason relative risk was reported, which allows scan 
characteristics to be used a part of risk stratification and risk management.   
Quantification of central trends in lesion burden provided continuous variables that allowed 
multiple options for statistical analysis.  These analyses, as was the case for Xpert and a 
history of previous PTB, showed up correlations more clearly.  For both MTB mRNA 
detection in sputum and BAL, however, we still could not find a strong correlation.  We did 
find a linear correlation between cavity volume and the number of MTB mRNA transcripts 
detected in BAL, but that may have been influenced by the single failed treatment case, for 
whom all transcripts were detected and who had an extensive lesion burden. 
In regards to EOT + 1y scans, the variation in timing between the scan and the recurrent 
disease diagnosis limited the conclusions we can draw from the data. 




We also found the heterogenic response pattern at a lesion level in the quantified intensity 
parameters.  This was shown by both changes in SUVmax during early treatment and 
infrequent complete resolution at the end of treatment.  Importantly, however, the more 
predictable changes in lesion burden throughout the lungs; and the strong correlation to 
serial microbiological investigations and clinical outcomes would suggest that PET/CT 
correlates with the extent of TB lung involvement and the MTB bacterial load in the lung. 
Therefor it suggests that PET/CT scans are useful for risk stratification and treatment 
response monitoring in therapeutic trials and assisting treatment decisions in complicated 
clinical cases, such as treatment of drug resistant TB and evaluation of adverse reactions to 
medication.  It also shows the importance of using quantification tools when reporting 
PET/CT scans in PTB patients. 
We found notable differences between failed and recurrent treatment cases.  Failed 
treatment was associated with extensive lung lesions at baseline and large cavities with thick 
walls at M6, as well as poor adherence.  Recurrent cases displayed a comparatively low 
lesion burden at baseline, average adherence and time to sputum culture negativity, but 
insufficient reduction in lesion burden during treatment.  We also found insufficient reduction 
in lesion burden in patients with a history of previous PTB episodes.  This raises important 
questions regarding the mechanisms underlying unfavourable outcomes.  It may indicate 
that patients who develop recurrent PTB disease have an insufficient immune response.  
However, the role that pharmacokinetics and MTB virulence factors play in this group also 
need further investigation.   
We found less reduction in cavity volume patients infected with the Beijing strain.  It is not 
clear if this was related to virulence factors regarding tolerance to drugs or host immunity. 
It was also surprising that the change in total glycolytic activity index showed a stronger 
correlation to sputum culture TTP at baseline and sputum Xpert positivity at M6, compared 
to cavity volume, which showed a stronger correlation to TTN, mRNA in BAL.  This supports 
the concept that the type of lesion plays an important part in the culturability of different MTB 
populations, and not only the bacterial burden, since lesions outside cavities may exist in an 
altered metabolic state.37 
The technique produced continuous variables representing the inflammatory lesion burden in 
the lungs and we proposed optimal thresholds, which could be used to form grouping 
variables.  This could be used as a tool to aid the discovery of biomarkers that could replace 
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more expensive and labour intensive PET/CT scans in risk stratification and individualised 
management decisions. 
Future research 
Various follow-up research projects are already underway or in advanced planning stages.   
Examples of using the quantified variables to aid biomarker discovery on the same cohort 
are shown in the next chapter.  
In a pilot project aimed at investigating possible end of treatment MTB persistence and 
improving its detection, a post-doctoral fellow, Dr Caroline Beltran, from our group is 
currently collaborating with Prof Bhavesh Kana (University of Witwatersrand).  We have 
recruited 26 additional PTB patients at the end of treatment.  We performed PET/CT scans 
on them and collected bronchoalveolar lavage fluid, post-bronchoscopy sputum, induced 
sputum and spot sputum samples.  We will attempt to replicate the scan analysis and mRNA 
assays.  In addition, we will conduct further gene expression analysis, and attempt to 
resuscitate viable, not conventionally culturable MTB, by applying and optimising 
resuscitation techniques adapted from methods developed by Prof Kana.  
We hope that more sensitive culture techniques would pave the way for better understanding 
of antibiotic and immune activity against MTB persistence.  In turn, this may lead to better 
immune modulation therapy to improve treatment outcome and perhaps decrease post 
tuberculosis lung sequelae.  
In an ongoing trial, we are collaborating with the Tuberculosis Research Section of the NIH 
and TASK applied science.  In this trial, PET/CT quantification is used in addition to sputum 
MTB CFU counts in determining the early bactericidal activity of different combinations of TB 
medication and the effect on different lesion types.  This study includes pharmacokinetic 
analysis. 
We are also involved in the advanced planning of a trial aimed at individualised treatment 
shortening for patients with a low baseline lesion extent, adequate reduction of total 
glycolytic activity on PET/CT at M1 and a high Xpert cycle threshold at month 4.  End of 
treatment scans would also be used to optimise and validate quantified criteria.  Other host 
biomarkers discovered in the current project would also optimised and validated with the 
goal to be used in place of more costly and labour intensive PET/CT scans in the future.  
This study will also include pharmacokinetic testing. 




Quantification of the PET/CT images significantly improved the prognostic accuracy of scans 
compared to qualitative scan patterns.  Risk stratification is already possible during early 
treatment and improves by the end of treatment.  A high cavity volume showed the strongest 
association with a risk of treatment failure, while a suboptimal reduction of the total glycolytic 
activity throughout the lung had the strongest association with recurrent disease.  Both these 
variables also correlated to microbiological markers.  This suggests a correlation between 
the quantified lesion burden and the MTB load.    
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7. Using quantified PET/CT variables to aid biomarker discovery 
7.1 Lesion burden and host inflammatory cytokines 
We evaluated 32 host protein biomarkers on serum samples from the study cohort, using a 
multiplex cytokine platform.  The laboratory work was led by Dr Novel Chegou and in this 
section, I present preliminary results from in-depth bio-informatics analysis performed by 
Prof Gerard Tromp at Stellenbosch University. 
Serum samples, collected at Dx, M1, M3 and M6 were analysed on the Luminex platform.  
We log transformed or scaled the cytokine data to be approximately normally distributed.  
For the Dx time-point, TGAI lesion burden of all participants was divided into tertiles.  Linear 
support vector machine (LSVM) models were developed from the cytokine data to predict 
which patients fell into the lowest tertile of TGAI measures (lowest risk for poor outcome).  
Four models were calculated and all showed AUCs of greater than 86% (Figure 44).  In 
addition, LSVM models were developed to indicate which patients fell within the highest 
tertile of TGAI burden.  The models all showed AUCs of greater that 90% (Figure 46). 
This could potentially serve as early low-risk prognostic indicator, which would be based on 
serum cytokine measurements rather than PET/CT imaging. 
Evaluation M6 samples to calculate predictive cytokine models, which accurately indicate 
patients with a high lesion load at the end of treatment that could serve as a high-risk 




    




Figure 44  ROC curves to show accuracy of host-protein markers to indicate low TGAI at Dx. 
Shaded area shows 95% confidence interval.  5, 9, 10 and 12 marker models were developed, all 
showed AUC’s of greater than 86%. 




Figure 45  The host proteins used in the 12-marker mathematical model. 
Spheres indicate specific host proteins, the size of the spheres the importance of the specific markers 
in the predictive model and the lines indicate a relationships between the specific markers in the 
model. 




Figure 46  ROC curves to show accuracy of host-protein markers to indicate high TGAI at Dx. 
Shaded area shows 95% confidence interval.  10 and 11 marker models were developed and all 











7.2 Lesion burden and host gene expression. 
Blood samples collected from the PTB cohort at Dx, M1 and M6 were sent to the Center for 
Infectious Disease Research in Seattle, Washington State, USA, for host-gene expression 
analysis (RNA Sequencing) to develop well-defined mathematical models for predicting 
outcome and discovering genes and pathways associated with different clinical outcomes. 
The analysis was led by Daniel Zak and Ethan Thompson.  The expression of thousands of 
host-genes were measured and compared to microbiological test results, clinical outcomes 
and quantified PET/CT data. 
TGAI and TGAIcom showed a very strong correlation to thousands of genes – at all time-
points and on all patients.  Examples of specific genes with a strong correlation include 
Gbp5 and Ankrd22 (shown in Figure 47).  More than 8000 genes had a false discovery 
probability of P < 0.01 and more than 2000 genes had a false discovery probability of P < 
0.00000001 (shown in Figure 48).  Host gene expression’s correlation with TGAI was 
stronger than with MGIT culture time to positivity and Xpert cycle time values. 
Further analysis are underway to use these correlations in developing a host-gene 
expression signature that could be used for risk stratification and treatment monitoring. 
 
Figure 47 Scatterplot of correlation between the expression of 2 host-genes and log (TGAI). 




Figure 48 Gene correlation TGAI, TGAIcom, Culture TTP and Xpert Cycle threshold value. 
The y-axis represent the number of genes and the x-axis the level of significance. 
7.3 Discussion: Biomarker discovery 
 We found a strong agreement between circulating host proteins and host-gene expression 
measured in peripheral blood, and the lung lesion burden as measured by automated 
segmentation techniques. This is reassuring and promising. 
It serves as further substantiation for:  
1) The usefulness of PET/CT in TB research.  
2) The robustness of the user-independent segmentation method.  
3) The importance of TGAI as a biomarker.   
4)  The feasibility of finding more easily measurable biomarkers in blood that correlate with 
the most important PET/CT variables. 
Peripheral blood is easily collected compared to more invasive sampling techniques, like 
bronchoalveolar or lung specimens and requires less resources than PET/CT scans.  It 
shows great promise that biomarkers measured from blood could be used to provide 
information regarding the lesion burden in lungs.  With further research these measurements 
could enriched as a prognostic indicator of morbidity (PTB recurrence and post-TB lung 
impairment) and mortality – leading to improved individualised management.  The markers in 
peripheral blood could also be used to build mechanistic hypotheses.  
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8. Concluding remarks 
Realisation of study objectives. 
In a major collaborative team effort, we successfully recruited and followed-up the participant 
targets set out.  We also successfully conducted in depth microbiological testing alongside 
the FDG-PET CT scans and collected a variety of specimens for biomarker discovery.  Very 
importantly, patients were well characterised and data captured in a study-specific database. 
Some additional goals were set (and accomplished) during the study, as new research 
questions came up.  These include:  1) Follow-up after treatment to determine outcome after 
treatment.  2) Performing bronchoscopies on patients at the end of treatment.  3) Performing 
an additional PET/CT scan 1 year after the end of treatment.   
Defining outcome after treatment proved especially challenging.  Factors adding to the 
challenge included:  1)  GeneXpert was  introduced in Cape Town clinics during the 
recruitment and follow-up and some healthcare providers were not yet very well informed 
about the complexity of a positive Xpert after treatment and the importance of sending 
sputum for a culture if a patient has recently completed treatment.  2)  It is not uncommon for 
doctors in primary care to initiate TB treatment on clinical suspicion, since the diagnosis of 
TB can be very difficult to prove, especially in patients with a previous history of TB and 
delaying treatment could be harmful. 
Scans were qualitatively evaluated and we reported a heterogenic response and a surprising 
discovery that most patients still have residual lesions showing a significant inflammatory 
response at end of treatment, in spite of clinical cure.  We also reported the presence of 
MTB mRNA in a significant proportion of patients’ sputum at the end of treatment and in BAL 
fluid for all patients that underwent this procedure.  This raised up important questions 
regarding the nature of host-pathogen interaction and the role an adequate immune 
response plays in maintaining a disease-free state after cure. 
We developed a technique requiring limited user input, that allowed that standardisation of 
PET uptake, based on a reference volume specific to the scan and the organ in question (in 
this case lungs), the auto-segmentation of lesions and the quantification of a variety of 
PET/CT characteristics at a voxel level.  We successfully implemented the method in all 
scans of included participants.   
The results correlated very well with microbiological and clinical data.  Therefore, we were 
able to define prognostic scan parameters.  Analysis are currently underway to use these 
quantified parameters as a tool for new biomarker discovery.  Early results appear very 
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promising.  Prognostic parameters might also be used to assist in the management of 
complicated clinical cases, such as MDR TB. 
In conclusion our results strongly suggest that PET/CT could be a useful tool in the 
monitoring the response to the treatment of pulmonary tuberculosis.  However, PET/CT is an 
expensive resource and only available in the large imaging facilities of countries with access 
to radioactive tracers.  This would imply that its use would most likely be limited to research 




A manuscript, entitled: ‘Persisting PET/CT lesion activity and Mycobacterium tuberculosis 
mRNA transcripts are common after curative treatment of pulmonary tuberculosis’ (Malherbe 
et al.) has been published in Nature Medicine.112  
Another manuscript, entitled ‘Bacterial loads measured by the Xpert MTB/RIF assay as 
markers of culture conversion and bacteriological cure in pulmonary TB’, (Shenai et al.), has 
been published in PLoS ONE.113  This manuscript describes the relationship between Xpert 
cycle time values and culture positivity and outcome. 
We have prepared an advanced draft of a manuscript entitled: ‘An operator independent 
technique to quantify widespread complex tuberculous lung lesions using PET/CT’, which we 
will shortly submit to a technical medical physics journal. 
A manuscript describing the quantified scan parameters and prognostic indicators is in 
advanced planning stages and will be submitted to a nuclear medicine journal. 
Further manuscripts describing novel biomarkers and their correlation to scan parameters 
are being planned. 
Personal role in project 
As a study clinician, I managed the nursing staff, supervised participant recruitment and 
assisted in procedures, like PET/CT scans and bronchoscopies.  I reviewed test results, 
including vitals, sputum microbiology, CXR's and PET/CT scans.  Firstly, from a clinical 
perspective, to ensure due diligence and inform the patient and appropriate healthcare 
providers of any information which might influence case management.  Secondly, I helped to 
clean data and consolidate clinical results.  I was also part of the team that determined and 
applied outcome definitions. 
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I took part in the discussions regarding the addition of the EOT bronchoscopies and the EOT 
+ 1y scans, made the protocol amendments and applied for ethical approval of the changes. 
I designed and applied the method to evaluate the PET/CT scans qualitatively.  Since only a 
minority of scans showed complete resolution, I devised a way to subdivide scan response 
patterns and grade intensity.  I adjusted the intensity grading system (the Deauville score) to 
allow monitoring of specific lesion progression or resolution.  To subdivide the response 
patterns, I used MIM Fusion software, to track the relative intensity of individual lesions from 
Dx to M6 and later from M6 to EOT + 1y to determine whether scans were resolved, 
improved or mixed.  I used the combined radiologist and nuclear physician scan reports to 
corroborate my findings and in case of any uncertainty, I asked Prof Walzl (pulmonologist) 
and Prof Warwick (nuclear physician) for a second opinion. 
The user independent method to quantify PET/CT images was conceptualised by Prof 
Warwick and Prof Dupont.  Prof Dupont and Ilse Kant (medical technology Masters student) 
wrote the first code for the MATLAB program and Prof Warwick evaluated and optimised it.  I 
assessed the application of the technique and made further changes to the method and 
script.  These included: defining the intensity and density thresholds, improving the way to 
create a lung mask accurately (by drawing the lung VOI and removing areas affected by 
motion misregistration).  After the technique was optimized, I applied it on all the scans 
included in analysis. 
Statistical analysis were performed on consolidated datasets I provided, by Prof Gerard 
Tromp, Tom Peppard, Lori Dodd, Yookwan Noh and myself.  More details regarding 
statistical analysis provided above, in Chapter 2.8. 
I also advised which qualitative and quantitative scan parameters seem the most important 
to aid further biomarker discovery. 
Personal statement 
It was a great privilege to be part of this project.  Firstly, I learned the scientific thinking 
process.  I also gained a lot of knowledge in the fields of immunology and microbiology, 
statistics, pulmonology, radiology and nuclear medicine.  My previous experience in multi-
disciplinary healthcare helped to give me insight in the important research questions. 
I was also introduced to an international collaboration.  It was an honour to network with 
great scientific minds.  I look forward to build on these partnerships in the future. 
I sincerely believe I can take the lessons I learnt while working on this project with me into 
the future and make an impact as a clinical researcher.  
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Appendix A  Patient demographics, outcome and scan response pattern. 
 Px 











1 30 F 9 Negative Yes Cure Improved Mild 
2 21 M 33 Positive Yes UE Mixed High 
3 66 M 0 Positive Yes Fail Mixed Very High 
4 40 M 0 Negative No Cure Resolved Minimal 
5 30 F 1 Negative No Cure Improved High 
7 58 M 0 Positive Yes Cure Mixed High 
9 19 M 12 Negative Yes Cure Improved Mild 
13 48 M 0 Negative Yes Cure Improved Moderate 
19 33 F 53 Positive Yes Fail Mixed High 
20 53 F 7 Negative Yes Cure Mixed Moderate 
21 46 M 21 Positive Yes Fail Mixed High 
22 29 F 1 Negative Yes Recur Improved Very High 
24 43 M 4 Negative Yes Cure Mixed High 
27 28 M 27 Positive Yes Fail Mixed Very High 
29 42 M 6 Negative Yes Cure Resolved Minimal 
30 25 M 4 Positive No Cure Improved Mild 
34 33 M 3 Positive Yes Recur Resolved Minimal 
35 28 M 32 Negative Yes Cure Mixed Moderate 
41 35 F 0 Negative Yes Cure Resolved Minimal 
42 32 F 6 Positive Yes Cure Improved Moderate 
43 18 M 0 Negative No Fail Mixed Moderate 
49 21 F 0 Negative No Cure Improved moderate 
50 38 M 0 Negative Yes Cure Improved High 
51 52 M 7 Negative Yes Cure Improved High 
52 44 F 0 Negative Yes Cure Improved High 
53 31 M 17 Negative Yes Cure Mixed Moderate 
54 55 M 0 Positive No Cure Resolved None 
70 27 M 6 Negative Yes Cure Mixed Moderate 
71 33 M 0 Negative Yes Cure Improved Mild 
72 25 M 3 Negative Yes Cure Improved High 
73 26 F 41 Negative Yes UE Resolved None 
76 36 M 0 Negative Yes Cure Resolved Minimal 
77 31 M 15 Negative Yes Cure Improved Mild 
78 39 M 0 Negative Yes Cure Improved Mild 
80 47 F 0 Negative Yes UE Improved Moderate 
81 22 M 2 Negative Yes Cure Mixed High 
83 22 M 5 Negative Yes Cure Improved High 
84 57 M 0 Positive No Cure Mixed Very High 
85 26 M 0 Negative Yes Cure Improved High 
86 19 F 0 Negative No Cure Improved High 
87 21 M 5 Negative Yes Cure Improved Mild 
88 46 M 0 Negative Yes Recur Mixed High 
89 25 F 82 Negative Yes Cure Mixed Moderate 
90 23 F 5 Negative Yes Cure Improved High 
91 28 M 7 Negative No Cure Improved Moderate 
92 42 M 0 Negative No Cure Mixed High 
93 30 M 0 Negative Yes Recur Improved High 
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95 46 M 4 Positive Yes Recur Mixed Moderate 
98 46 F 0 Negative Yes Cure Mixed High 
99 37 F 0 Negative Yes Cure Mixed High 
100 55 F 9 Negative Yes Cure mixed Very High 
101 28 F 12 Positive Yes Recur Improved High 
102 39 F 0 Negative Yes Cure Mixed Moderate 
103 43 F 0 Positive Yes Cure improved Moderate 
104 42 M 0 Negative No Cure Mixed High 
105 21 M 0 Negative Yes Cure Resolved Minimal 
108 29 M 0 Negative Yes Cure Improved Moderate 
111 22 M 0 Negative Yes Cure Improved Moderate 
112 52 M 2 Negative Yes Recur Mixed High 
123 40 M 0 Positive Yes Cure Mixed High 
124 24 M 32 Negative Yes Cure Improved Mild 
125 32 M 0 Negative Yes Cure Improved Mild 
126 39 M 1 Negative No Cure Improved Moderate 
128 22 M 15 Positive Yes Cure Improved High 
129 39 M 9 Negative Yes Cure Improved Moderate 
130 29 M 1 Negative Yes Recur Improved Mild 
131 18 F 0 Negative No Cure Improved Very High 
132 17 F 15 Negative Yes Cure Mixed High 
133 33 F 10 Positive Yes Cure Improved High 
134 24 F 0 Negative Yes Cure Resolved Minimal 
135 17 M 2 Negative No Cure Improved Very High 
136 41 M 0 Negative Yes Cure Improved High 
137 44 F 0 Positive Yes Recur Improved High 
138 23 M 11 Negative Yes Cure Improved High 
139 38 M 31 Negative Yes Cure improved Moderate 
140 22 M 25 Positive Yes Recur improved Mild 
141 17 M 5 Negative Yes Cure Resolved None 
142 43 F 0 Positive Yes Recur Mixed Very High 
144 31 M 21 Negative Yes Cure Mixed High 
145 19 F 11 Negative Yes Cure Improved High 
146 20 M 0 Positive Yes Cure Improved High 
147 23 M 0 Negative No Cure Mixed Very high 
149 19 F 4 Negative No Cure Improved Moderate 
150 21 F 56 Positive No Cure Mixed High 
152 23 F 0 Negative Yes Recur Improved High 
153 25 M 53 Positive Yes Cure Resolved Minimal 
154 42 F 0 Positive Yes Cure Improved High 
155 36 F 2 Negative No Cure Resolved Minimal 
156 64 M 0 ? Yes Cure Mixed High 
159 19 F 0 Negative No Cure Resolved Minimal 
160 40 F 0 Negative No Cure Improved Moderate 
161 25 F 7 Positive No Cure Improved High 
162 49 M 1 Positive Yes Cure Improved Moderate 
163 25 M 3 Positive Yes Fail Mixed High 
167 41 M 2 Negative Yes Cure Improved High 
168 23 F 86 Positive No Fail Mixed Very High 
169 30 F 91 Positive Yes Fail Mixed Moderate 
170 30 F 33 Negative Yes Cure Resolved None 
171 45 F 0 Positive Yes Cure Improved High 
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Appendix B  EOT + 1y scan response patterns per patient. 











76 Cure Mixed very high 6.5 Resolved Minimal 
77 Cure Resolved Minimal 1.6 Improved Mild 
78 Cure Resolved Minimal 1.5 Improved Mild 
80 UE Improved Mild 2.8 Improved Moderate 
81 Cure Mixed Moderate 3.2 Mixed High 
84 Cure Improved High 4.3 Mixed Very high 
85 Cure Improved Mild 2 Improved High 
86 Cure Improved Mild 2.3 Improved High 
88 Recur Mixed High 2.7 Mixed High 
89 Cure Resolved None 0.9 Mixed Moderate 
90 Cure Resolved Minimal 2 Improved High 
91 Cure Mixed Moderate 2.3 Improved Moderate 
92 Cure Improved Moderate 2.2 Mixed High 
93 Recur Mixed High 4.2 Improved High 
95 Recur Improved Moderate 2.4 Mixed Moderate 
98 Cure Mixed Very high 7.5 Mixed High 
99 Cure Resolved Minimal 1.9 Mixed High 
100 Cure Improved Mild 2.2 mixed Very High 
102 Cure Resolved Minimal 1.2 Mixed Moderate 
103 Cure Resolved Minimal 1.6 improved Moderate 
104 Cure Resolved Minimal 1.3 Mixed High 
105 Cure Resolved None 0.8 Resolved Minimal 
111 Cure Resolved Minimal 1.5 Improved Moderate 
112 Recur Mixed Very High 5.4 Mixed High 
124 Cure Resolved Minimal 1.1 Improved Mild 
125 Cure Improved Moderate 2.6 Improved Mild 
126 Cure Resolved Minimal 1.6 Improved moderate 
128 Cure Mixed High 4.7 Improved High 
129 Cure Resolved Minimal 1.2 Improved Moderate 
131 Cure Resolved None 0.6 Improved Very high 
132 Cure Mixed Moderate 2.8 Mixed High 
133 Cure Mixed High 4 Improved High 
135 Cure Improved High 4.6 Improved Very high 
137 Recur Improved Moderate 3.8 Improved High 
138 Cure Improved Mild 1.8 Improved High 
139 Cure Mixed High 2.4 improved Moderate 
140 Recur Improved Mild 1.6 improved Mild 
141 Cure Mixed High 2.1 Resolved None 
142 Recur Mixed Very high 7.8 Mixed Very high 
145 Cure Improved Moderate 2.1 Improved High 
146 Cure Mixed high 3.8 Improved high 
149 Cure Improved Mild 1.8 Improved Moderate 
152 Recur Mixed Moderate 1.4 Improved high 
154 Cure Improved Mild 1.8 Improved high 
155 Cure Resolved Minimal 0.6 Resolved Minimal 
156 Cure Mixed Moderate 2.1 Mixed High 
161 Cure Improved Mild 1.7 Improved high 
162 Cure Resolved Minimal 1.8 Improved Moderate 
167 Cure Mixed High 3.6 Improved High 
171 Cure Improved mild 2.1 Improved High 
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Appendix C  South Korea patient demographics, outcome and scan response. 
Px ID Age Gender Smoking 
Previous 







A225 65 Male Yes No MDR Cured Good Resolved Minimal  
A226 63 Male Yes No DS Cured Good Improved Moderate 
A227 57 Male Yes No R mono Cured Good Mixed Very high 
A228 65 Male No No DS Cured Good Mixed Very high 
A230 57 Male No No DS Cured Good Mixed Very High 
A238 45 Female Yes No DS Cured Poor Improved Moderate 
A240 27 Female No No DS UE  Good Mixed Very High 
B449 56 Male Yes Yes DS Recurrence Good Improved Mild 
B450 50 Male Yes Yes DS Cured Good Mixed Very High 
B452 66 Male Yes Yes R mono Cured Good Mixed Very High 
B453 24 Male No Yes MDR Cured Good Improved Moderate 
B459 61 Male Yes Yes MDR Cured Good Improved Mild 
B462 26 Male No Yes DS Cured Good Mixed Moderate 
B463 51 Male No Yes DS Cured Good Improved High 
 
New lesions: 4 
2 Nodular infiltrates 
1 Consolidation 
1 Tree in bud 
 Old More intense 
3 Cavity, 2 now consolidation 
1 Nodule, now consolidation 
1 Nodule, more intense 
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Appendix D  Sputum MTB mRNA copy numbers and clinical status. 
Pulmonary Tuberculosis patients 
 
Patient Outcome 85B DOSR PRCA ICL PSTS1 NUOB Rv2623 ACR CARD TGS1 TB 8.4 ACPM RRN Total
41 Cure 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
42 Cure 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1
43 Fail 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 2
49 Cure 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
50 Cure 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
51 Cure 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
52 Cure 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
53 Cure 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
54 Cure 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
70 Cure 0.0 1.6 0.0 0.0 0.0 2.4 0.0 72.3 0.0 5.2 0.0 6.6 1.8 6
71 Cure 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
72 Cure 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
73 UE 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
76 Cure 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
77 Cure 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.1 0.0 0.0 0.0 1.1 0.0 2
78 Cure 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 2
80 UE 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1
81 Cure 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.1 0.0 0.0 0.0 0.0 0.0 1
83 Cure 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
84 Cure 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
85 Cure 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
86 Cure 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.2 0.0 0.0 0.0 0.0 4.9 2
87 Cure 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.3 0.0 0.0 0.0 0.0 0.0 1
88 Recur 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
89 Cure 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
90 Cure 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
91 Cure 0.8 0.0 0.0 0.0 0.0 0.0 0.0 6.0 0.0 0.0 0.0 0.0 0.0 2
92 Cure 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
93 Recur 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
95 Recur 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
98 Cure 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
99 Cure 0.0 0.0 0.0 0.0 7.7 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.0 2
100 Cure 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
101 Recur 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
102 Cure 0.0 0.0 0.0 0.0 0.0 0.0 0.0 20.0 0.0 0.0 0.0 0.0 0.0 1
103 Cure 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
104 Cure 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
105 Cure 0.0 0.0 0.0 0.0 0.0 0.0 0.0 38.3 0.0 1.3 0.0 1.5 2.6 4
108 Cure 0.0 0.0 0.0 0.0 0.0 0.0 0.0 15.5 0.0 0.0 0.0 0.0 0.0 1
111 Cure 5.8 0.0 0.0 0.0 0.0 0.0 0.0 9.4 0.0 0.0 0.0 0.0 3.8 3
112 Recur 0.0 0.0 0.0 0.0 0.0 0.0 0.0 32.3 0.0 1.6 0.0 3.6 1.3 4
123 Cure 0.0 0.9 2.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 1.9 4
124 Cure 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.9 0.0 0.0 0.0 1.5 0.8 3
125 Cure 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
126 Cure 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
128 Cure 0.0 0.0 0.0 0.0 0.0 0.0 0.0 39.2 0.0 0.0 0.0 7.6 3.0 3
129 Cure 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
130 Recur 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
131 Cure 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.8 0.0 0.0 0.0 0.0 0.0 1
132 Cure 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
134 Cure 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
135 Cure 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.5 0.0 0.0 0.0 0.0 1.3 2
136 Cure 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
137 Recur 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
138 Cure 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
139 Cure 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
142 Recur 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.0 1
144 Cure 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.8 0.0 1
145 Cure 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
147 Cure 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 1
149 Cure 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 1
150 Cure 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
152 Recur 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
154 Cure 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
155 Cure 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
156 Cure 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
160 Cure 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
161 Cure 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
162 Cure 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
163 Fail 0.0 5.9 0.0 0.0 0.0 1.1 0.0 18.6 0.0 1.7 0.0 2.6 4.8 6
167 Cure 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
168 Fail 0.0 122.5 0.0 112.4 0.0 0.0 145.2 1584.5 1526.7 0.0 197.1 835.7 224.7 8
169 Fail 4.6 32.6 35.1 14.7 21.7 125.5 45.5 658.0 594.3 118.1 81.0 23.0 71.2 13
170 Cure 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
171 Cure 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.3 0.0 1
Total pos 4 6 3 2 2 4 2 20 2 5 2 16 12 29






ID Sex Age Outcome Quantiferon® 85B DOSR PRCA ICL PSTS1 NUOB TB37.1 HspX CARD TGS1 TB 8.4 ACPM RRN Total 
S6 Male 33 Community Positive 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
S10 Female 21 Community Positive 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
S11 Female 45 Community Positive 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
S18 Female 26 Community Positive 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
S36 Female 40 Community Positive 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
S37 Female 60 Community negative 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
S38 Male 21 Community Positive 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
S39 Female 24 Community Positive 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
S45 Female 34 Community Positive 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
S48 Male 25 Community Positive 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 1
S60 Male 26 Community Negative 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
S61 Male 23 Community Positive 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
S62 Male 22 Community Positive 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
S63 Male 20 Community Positive 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
S65 Female 48 Community negative 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
S66 Female 34 Community Positive 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
S67 Female 50 Community Positive 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
S68 Female 23 Community Positive 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
S181 Male 27 Community negative 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
S182 Male 27 Community negative 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 1
S172 Female 60 OLD Positive 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
S173 Female 62 OLD negative 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
S175 Male 49 OLD Positive 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
S177 Female 28 OLD Positive 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
S178 Male 26 OLD Negative 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0
Total 0 0 0 0 0 0 0 0 0 1 0 1 0 2
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Appendix E  MTB mRNA copy numbers in Bronchoalveolar lavage and clinical status 
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Appendix F  Primer sequences for MTB mRNA  
 List of Primer sequences for transcription of MTB RNA targets used for RT-PCR in M6 
sputum.  (Shubhada and Alland) 
No Targets Primers and Molecular Beacon Sequences 
1. DOSR DOS R RT -  CCC TTG ATG TCT TTG ACG ACA 
DOSR F -     GAT CCT CAC GTC CTA CAC CTC 
DOSR R -     GAC GAC ATA TCC GCT GGC ACC 
DOSR MB  - AGCCG CTGACGAGGCCATGCTAGATG CG 
TCGGC 
2. 85B 85 B RT  -   GGG TGC CGT TCC CGC AAT AAA 
85B F -        CAA CGA CCC TAC GCA GCA GAT C 
85B R -        TTC CCG CAA TAA ACC CAT AGC 
85B MB -      CGCTG CAAGCTGGTCGCAAACAACACCCG 
CAGCG 
3. ICL ICL RT -       GCC GCG AGC CGA GCA GAC GT 
ICL F -         CTG AGA AGA AGT GCG GCC AC 
ICL R -         AGA CGT CAA AGT GCG GAT GTG 
ICL MB -      CTC GGGCGGCAAGGTGTTGATCCC GAG 
4. NUOB NUOB RT -   AGC GCG TTC CCG GTT GAT ACC 
NUOB F -     GCT GCA CGC AAT CCT GAA GCT 
NUOB R -     CCG GTT GAT ACC TAA TGG CAT C 
NUOB MB -  CGC GCACGAAAAGATTCAGCAGATGC GCG 
5. ACPM ACPM RT -   GTC GAT GTC CAG GTC GTC GA 
ACPM F -     CCG GTA TCG AGC CGT CCG AGA 
ACPM R-      GGT CGT CGA CGA ACG ACT TC 
ACPM MB -  ACGC GAGATCACCCCGGAGAAGTC GCGT 
6. PSTS1 PSTS1 RT -  TCG AAA TCG CCT GGT TCG CCG 
PSTS1 F -    GCC CGA CGC GCA AAG CAT TCA 
PSTS1 R -    GCC TGG TTC GCC GGG GTT TTC 
PSTS1 MB - CCACC GCGGCTGGCTTCGCATCGAAAAC 
GGTGG 
7. PRCA PRCA RT -   GCA GCG ACC GCG ATA CGC AG 
PRCA F -     GAT CGC CAA CGC GCT CAA AGA 
PRCA R -     CGC AGG GCG TCG GTC AGG CT 




ACR RT -    GGT GGC CTT AAT GTC GTC CTC GTC 
ACR F -       GAC GGT CGC TCG GAA TTC GCG TAC 
ACR R -       CGT CCT CGT CAG CAC CTA CCG GC 
ACR MB -    CGCTCC CCTTCGTTCGCACGGTGTCGCTG 
GAGCG  
9. CARD CARD RT - CGG GGC ACG CAA CAC CTG GAA 
CARD F -    CGA CCT GAC AGT ACG AGT TCC C 
CARD R -    GCC TTC CTG CCC GAC GAC ATC 
CARD MB - AG CCCGCTGAAAACGCCGAATACG GGCT 
10. TGS1 TGS1 RT -  CGA GAC CGG CAC TAG CGT ACG 
TGS1 F -     ATG TTG CGC TTG CCG CGA TTA CGG 
TGS1 R -     CGA ATC AAA CCT AGG CCG CTC ACC 
TGS1 MB -  ACGC CTACCGCAACGTCCTCATCCAG GCGT 
11. TB 8.4 TB 8.4 RT -  GGT GTT AAT GAC CGC GTC CAC G 
TB 8.4 F -    CGC ATT GAG CGC CGG TGT AGG C 
TB 8.4 R -    CTG CGG AGG CGA CCC CGG CCC 
TB 8.4 MB -  ACG CCGTGGCAATGTCGTTGACCG GCGT 
12.  Rv2623 RV2623 RT - CCA CCG CCC ACT TCC GAG ACA AC 
Rv2623 F -    GGC AGC CGT TCC CAC ATT GG 
Rv2623 R -    CCG AGA CAA CCC ACG ACC AT 
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Rv2623 MB -  CGACC GGTCGACATGTCCAAAGACGC 
GGTCG 
13. SIGA SIGA RT -     ATC TGG CGG ATG CGT TCC CGG 
SIGA F -        GGC CAG CCG CGC ACC CTT GAC 
SIGA R -       CGG ATG CGT TCC CGG GTC ACG 
SIGA MB -    CGC  ACG AGA TCG GCC AGG TCT ACG GCG 
T GCG 
 
14. RRN RRN RT -     TTC TCA AAC AAC ACG CTT GCT TG 
RRN F -       CCT ATG GAT ATC TAT GGA TGA C 
RRN R -       GCA ACC CTG CCA GTC TAA TAC AA 
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